The interplay between Notch and somatostatin
receptors in pancreatic neuroendocrine tumours

Iida-Maria Laiho, 38882
Email: ilaiho@abo.fi
27.1.2020
Pro gradu
223996.0, 40 credits
Cell biology
Faculty of science and engineering
Åbo Akademi University
Supervisors:
Prof. Cecilia Sahlgren
Valeriy Paramonov, MD
Veronika Mamaeva, MD

Åbo Akademi University

Iida-Maria Laiho

Department of biosciences
Faculty of Science and Engineering

The interplay between Notch and somatostatin receptors in pancreatic
neuroendocrine tumours
Master’s thesis

Abstract
Pancreatic neuroendocrine tumours (PNETs) are rare malignancies with limited treatment
options. Notch pathway has been reported to have low activity in PNETs, which suggests its
role as a tumour-suppressor. Until now, only a few experimental studies exist of Notch in
PNETs and thus the function of Notch in PNETs remains poorly understood. PNETs
overexpress somatostatin receptors (SSTRs) and activation of SSTRs reduces cell
proliferation as well as hormone secretion. Thus, SSTRs are often targeted in PNETs for
therapeutic purpose. Initial experiments in C. Sahlgren’s group showed that inhibition of the
Notch ligand JAG1 in vivo reduced tumour progression in mice, which were transplanted with
the PNET cell line BON1 where SSTR5 was knocked out (KO). BON1 cells with both
SSTR5 and SSTR2 KO also showed increased JAG1 levels. With this data in view, my
research was aimed to further elucidate the possible connection between Notch and SSTR
signalling in PNETs. To study the interaction between Notch and SSTR5, I used western blot
to analyse the protein levels of Notch receptors and JAG1. I also studied proliferation of
BON1 cells with cell counting and WST8 assay. However, no differences in Notch receptor
and JAG1 protein levels, or in proliferation were observed. When I studied functionality of
the Notch pathway with co-cultures and plates coated with JAG1 peptides, differences in CSL
activity could be coupled SSTR5 expression. However, the two methods produced varying
results, which calls for additional validation. Further studies on how SSTR5 affects
transcriptional activity of CSL and which of the four Notch receptors is in charge of the
altered Notch transcriptional response in our model of PNETs are required.
Keywords: Notch, JAG1, pancreatic neuroendocrine tumour, somatostatin receptor

Åbo Akademi

Iida-Maria Laiho

Institutionen för biovetenskaper
Fakulteten för naturvetenskaper och teknik

Samspelet mellan Notch och somatostatin receptorer hos bukspottskörtelns
neuroendokrina tumörer
Pro gradu-avhandling

Abstrakt
Bukspottskörtelns neuroendokrina tumörer (PNET, eng. pancreatic neuroendocrine tumours)
är sällsynta tumörer med låg Notch-aktivitet och därför antas Notch-signaleringen fungera
som en tumörsupressor hos PNET:er. Efter som det endast finns få studier om Notch i
PNET:er, är kunskapen om Notch i PNET:er fortfarande dåligt. PNET:er överuttrycker
somatostatinreceptorer (SSTR) vars aktivering minskar proliferation och hormonutsöndring.
Därmed har läkemedel som aktiverar SSTR:er utvecklats. Tidigare i C. Sahlgrens grupp har
inhibering av Notch-liganden JAG1 in vivo visat minska tumörstorleken hos möss som
transplanterades med PNET-cellinjen BON1 utan SSTR5-uttryck. Dessutom detekterades
högre JAG1-protein uttryck i BON1-celler som saknade både SSTR2 och SSTR5. För att
studera kopplingen mellan Notch-signaleringen och SSTR, användes western blot för att
analysera Notch-receptor- och JAG1-proteinnivåerna. Jag analyserade också proliferationen
hos dessa celler med cellräkning och WST8-analys. Skillnader i Notch receptor och JAG1proteinnivåer, samt proliferation detekterades inte. Då Notch-aktiviteten i BON1-celler
undersöktes med samkultur och plattor som var täckta med JAG1-peptider, detekterades
skillnader i Notch-aktivitet, som kunde kopplas till SSTR5-uttryck. Men, samkulturen och
JAG1-peptiderna visade varierande resultat och funktionen av de två metoderna borde
bekräftas. Dessutom, är det ännu oklart hur SSTR5 påverkar transkriptionella aktiviteten hos
CSL och vilken av de fyra Notch receptorerna var påverkad av SSTR5.
Nyckelord: Notch, JAG1, bukspottskörtelns neuroendokrina tumörer, somatostatinreceptorer

Table of contents
1 Literature overview..............................................................................................................6
1.1 Pancreatic neuroendocrine cells.....................................................................................6
1.2 Pancreatic neuroendocrine tumours ...............................................................................6
1.2.1 Classification of neuroendocrine tumours ...............................................................7
1.2.2 Genetic alterations in pancreatic neuroendocrine tumours .......................................9
1.2.3 Diagnostics of pancreatic neuroendocrine tumours ..................................................9
1.2.4 Hereditary diseases associated with PNETs .......................................................... 11
1.2.5 Current treatments ................................................................................................ 11
1.3 Somatostatin and somatostatin receptors .....................................................................13
1.3.1 SSTR molecular signalling ................................................................................... 14
1.3.2 Regulation of SSTR signalling .............................................................................. 15
1.3.3 Somatostatin receptors in pancreatic neuroendocrine tumours ............................... 16
1.4 Overview of Notch signalling pathway ........................................................................17
1.4.1 Structure of Notch receptors and ligands ............................................................... 17
1.4.2 Notch signalling pathway...................................................................................... 19
1.4.3 Regulation of Notch signalling.............................................................................. 21
1.4.4 The role of Notch in development of pancreatic endocrine cells and pancreatic
neuroendocrine tumours ................................................................................................ 24
2 Previous research, hypothesis and aims.............................................................................. 26
3 Materials and methods .......................................................................................................28
3.1 Cell culture ................................................................................................................. 28
3.2 Western blot ................................................................................................................ 29
3.2.1 Lysate preparation ................................................................................................ 29
3.2.2 Protein quantitation with Pierce 660 nm assay ...................................................... 29
3.2.3 Western blot ......................................................................................................... 30
3.3 WST8 assay ................................................................................................................ 31
3.4 Reporter assay for Notch activity ................................................................................ 32
3.4.1 Plasmids and transfections .................................................................................... 32
3.4.2 Dual-Glo luciferase assay ..................................................................................... 32
3.5 Notch activation with ligand peptides .......................................................................... 33
4 Results ............................................................................................................................... 34
4.1 Profiling BON1 cells for Notch receptors and ligands ................................................. 34
4.2 SSTR2 and SSTR5 expression does not affect proliferation of BON1 cells in vitro .....36
4.3 BON1 SSTR5 KO cells show enhanced Notch response to JAG1 stimulation ............. 37

5 Discussion ......................................................................................................................... 40
5.1 SSTR levels does not affect expression of Notch receptors and JAG1 in BON1 cells ..40
5.2 Expression levels of SSTR2 and SSTR5 do not affect proliferation in BON1 cells in
vitro ..................................................................................................................................40
5.3 BON1 cells obtain altered responsiveness to JAG1 stimulation with loss of SSTR5 .... 42
6 Conclusions ....................................................................................................................... 44
7 Acknowledgements ........................................................................................................... 45
8 References ......................................................................................................................... 46
9 Supplementary figures .......................................................................................................59
10 Recipes and buffers.......................................................................................................... 60
11 Svensk sammanfattning ...................................................................................................61
11.1 Introduktion .............................................................................................................. 61
11.2 Hypotes och målsättning ........................................................................................... 64
11.3 Material och metoder................................................................................................. 65
11.3.1 Celler .................................................................................................................. 65
11.3.2 WST8 ................................................................................................................. 65
11.3.3 Western blot .......................................................................................................66
11.3.4 Experiment med rapportörgen ............................................................................. 67
11.4 Resultat ..................................................................................................................... 67
11.4.1 Profilering av Notch-receptorer och JAG1 hos BON1-celler ............................... 67
11.4.2 Proliferation hos BON1-celler med olika SSTR2- och SSTR5-uttryck ................ 68
11.4.3 BON1 som Notch-signalmottagande celler.......................................................... 68
11.5 Diskussion................................................................................................................. 69

Abbreviations
CgA

Chromogranin A

CSL

CBF1/RBPJ, Su(H) and Lag-1

GEP-NET

Gastroenteropancreatic neuroendocrine tumours

GPCR

G-protein coupled receptor

HPF

High Power Fields, visible area under maximal objective magnification
power

HRP

Horseradish peroxidase

KO

Knockout

NICD

Notch intracellular domain

NECD

Notch extracellular domain

NRR

Negative regulatory region

NSE

Neuron specific enolase

OE

Over expression

PNEC

Pancreatic neuroendocrine carcinoma

PNET

Pancreatic neuroendocrine tumour

RT

Room temperature

SST

Somatostatin

SSTR

Somatostatin receptor

TNM

Tumour-node-metastasis, a staging system utilised in oncology

VEGFR

Vascular Endothelial Growth Factor Receptor

5

1 Literature overview
1.1 Pancreatic neuroendocrine cells
The pancreas incorporates 1-3 million islets of Langerhans, which comprise circa 1-2%
of its total volume. The islets consist of neuroendocrine cells, which are closely
associated with blood vessels and regulate blood glucose levels through secreting
hormones. Additionally, some endocrine cells are also scattered in the large pancreatic
interlobular ducts. Majority of the islet cells are insulin-producing β cells (~60%),
followed by glucagon-producing α cells (30%), somatostatin (SST) -producing δ cells
(10%) and pancreatic polypeptide-producing cells (<5%). In humans, these cell types
are randomly scattered in the islets. In some species, for example mouse (Mus
musculus), the islets have a specific architecture, where β cells sit in the centre of the
islet and are surrounded by α- and δ cells (Cabrera et al., 2006).

1.2 Pancreatic neuroendocrine tumours
Pancreatic neuroendocrine tumours (PNET) are understudied malignancies that
comprise about 1-2% of all pancreatic neoplasms, which makes PNETs the second-most
common type of pancreatic cancer. PNETs are morphologically and clinically
heterogeneous, with the majority of tumours being asymptomatic, which causes late
diagnosis with PNETs detected already at advanced stage (Kelgiorgi & Dervenis, 2017).
The median survival in all PNETs is 3.6 years and depends on tumour grade and
localisation. Patients with localised or low proliferating tumours have better survival as
compared to patients with advanced metastatic or highly proliferative PNETs (Dasari et
al., 2017). Among factors, associated with increased survival, are the patient`s age and
primary tumour localisation in the head of the pancreas (Keutgen et al., 2016).
According to the cancer registry Surveillance, Epidemiology, and End Results 18
(SEER18), the combined NET incidence across all tumour stages and sites was 6.98 per
100 000 in 2012, which made a 6.4-fold increase since 1973 (1.09 per 100 000) in
United States of America. A higher incidence has been documented in patients with age
of 65 or older (25.3 per 100 000) (Kelgiorgi & Dervenis, 2017). NET detection has also
increased in European countries. In the United Kingdom the incidence in GI-NETs has
increased 3.8-fold in females and 4.8-fold in males between 1937 and 2007. In Norway
the PNET incidence has increased from 0.15 to 0.3 between 1993 and 2004 (Hauso et
al., 2008; Fraenkel et al., 2014). The reasons for this increase in PNET incidence is not
6

well understood, but it is likely to be related to improved diagnostic methods and higher
frequency of abdominal imaging, facilitating detection of small and asymptomatic
tumours at earlier stages. Currently, surgery is the only effective option for tumour
removal (Kelgiorgi & Dervenis, 2017).

1.2.1 Classification of neuroendocrine tumours
Classification systems are important for patient prognosis and treatment determination,
and are often based on molecular markers and tumour imaging. One way to classify
NETs is based on hormone secretion. NETs that do not produce hormones are
designated as non-functioning NETs (NF-NET). This type of NETs is estimated to
constitute 60-90% of all NETs (Kelgiorgi & Dervenis, 2017). NF-NETs are usually
asymptomatic and often detected only when they have become advanced, thus circa
60% of the cases will have metastases by the time of diagnosis (Keutgen et al., 2016).
The rest of NETs are so-called functioning tumours (F-NET) that hypersecrete at least
one type of hormone. Examples of F-NETs are insulinomas (30-45% of all F-NETs),
gastrinomas (16-30%), glucagomas, vasoactive intestinal peptid-secreting tumors
(VIPomas, <10%), and somatostatinomas (<5%). In F-NETs, symptoms mainly depend
on the type of hormone a tumour secretes. Insulinomas cause hypoglycaemia due to
excessive insulin production, whereas symptoms caused by glucagomas include
diabetes and migratory necrolytic erythema (a type of rash) (de Wilde et al., 2012).
In the WHO 2010 classification system of GEP-NETs, mitotic count and the Ki-67
proliferation index are used to categorise PNETs in three groups, NET grade 1 (G1),
NET G2 and neuroendocrine carcinomas G3 (PNEC) (Figure 1) (Luo et al., 2017).
Mitotic index is usually measured by counting the number of mitotic cells divided by
the number of non-mitotic cells under 400x magnification (Meuten et al., 2016). Ki-67
is a nuclear protein, which is expressed in all phases of the cell cycle, except G0 phase.
Thus, Ki-67 is used as a marker for actively proliferating cells and has a prognostic
value (Scholzen & Gerdes, 2000). NET G1 and G2 are well-differentiated tumours, with
NET G1 having mitotic count <2/10 HPF and Ki-67 index <2, and NET G2 having 220/10 HPF and Ki-67 index of 3-20. PNECs are poorly differentiated tumours with Ki67 index and mitotic count >20% and >20/10 respectively and patients with PNEC have
a higher possibility to develop metastasis in the lymph nodes or the liver (Luo et al.,
2017).

7

Figure 1: The WHO 2010 classification system of GEP-NETs. The system divides tumours into three
categories, based on the proliferation marker Ki-67 and the number of mitoses. From Luo et al., 2017,
modified.

Though the WHO classification has been validated and has established prognostic
value, it provides no information on disease stage. Thus, to supplement it, two different
staging systems have been developed: tumour-node-metastasis (TNM) staging system
of the American Joint Committee on Cancer (AJCC) and TNM system of the European
Neuroendocrine Tumor Society (ENETS). In the AJCC and ENETS staging systems
tumours are categorised according to the size of the primary tumour (T) and extent of
the metastatic spread (metastases to lymph nodes (N) or distant metastases (M)) (Figure
2).

Figure 2: AJCC and ENETS classification systems. The definitions used to stage PNETs according to
the ENETS and AJCC. Image modified from Luo et al., 2017.

The use of two classification systems could cause confusion. In ENETS, the prognosis
of stage I and IIA tumours are similar and stage IIIA patients have a higher death rate
than stage IIIB patients. In the AJCC, stage III tumours are associated with mesenteric
and celiac vessels although PNETs do not usually invade these vessels. Thus, it has
been suggested to create one system for tumour staging by incorporating the staging of

8

AJCC into the TNM of ENETS, but with maintaining principal definitions of ENETS
system (Figure 3) (Luo et al., 2017).

Figure 3: A modified version of the ENETS and AJCC classification system for PNETs. The new
suggested classification system keeps the primary tumour (T), lymph nodes (N) and distant metastasis
(M) definitions from ENETS and incorporates staging of AJCC. From Luo et al., 2017, modified.

1.2.2 Genetic alterations in pancreatic neuroendocrine tumours
The most common mutation in PNETs, but not in PNECs, is a deletion or loss of
function in the MEN1 gene (44.1%), which encodes the protein menin. Menin plays an
important role in the mixed lineage leukemia/Su(var)3‐9, Enhancer of Zeste, Trithorax
(MLL/SET) -like histone methyltransferase complex, which regulates the transcription
of genes in a cell-type-specific manner. In the islet cells, menin regulates the cell cycle
by activating the transcription of cyclin-dependent kinase (CDK) inhibitors (de Wilde et
al., 2012; Missiaglia et al., 2011). PNETs have also been reported to harbour deletions
or loss of function of two chromatin-remodelling proteins, death domain-associated
gene (DAXX, 25%) and alpha thalassemia/mental retardation syndrome X-linked
(ATRX, 17.6%). The protein products of DAXX and ATRX form a heterodimer, which is
required for recruitment of histone 3.3 (H3.3) to the telomeres. Mutation in one or both
of these genes causes genomic instability in PNETs (Jiao et al., 2011).
The phosphoinositide 3-kinase (PI3K) pathway is also frequently affected in PNETs,
with PTEN and TSC2 expression often being downregulated. In normal state, PTEN
and TSC2 negatively regulate the PI3K pathway, which causes inhibition of cell
proliferation. In PNETs, both proteins are frequently downregulated and this correlates
with decreased progression-free survival (Missiaglia et al., 2010; Jiao et al., 2011).

1.2.3 Diagnostics of pancreatic neuroendocrine tumours
Molecular markers are important for tumour detection, characterisation and treatment
decisions. F-PNETs can be diagnosed by biochemical analyses for hormones or
peptides secreted by the tumour, and by the symptoms caused by the hypersecretion.
For example, patients with insulinomas can suffer from hypoglycaemia, whereas
9

patients with somatostatinomas tend to have general inhibition of hormone secretion,
which results for example in diarrhoea, anemia and hypochlordyria (de Wilde et al.,
2012). In NF-PNETs, however, other markers are needed for tumour identification and
prediction of survival. Although NF-PNETs do not produce hormones, they still secrete
vesicles containing various bioactive substances. Out of these, chromogranin A (CgA)
is used as a general serum PNET marker since it has been validated in many studies and
has a predictive value (high CgA levels have been linked to poor progression free
survival) (Yao et al., 2011). However, CgA can also be elevated in other disorders
unrelated to NETs, for example Parkinson’s disease, breast cancer and heart failure
(Marotta et al., 2012). Neuron-specific enolase (NSE) is another circulatory protein,
which has also been used as a NET marker. In one clinical study low levels of CgA and
NSE and were associated with better survival. Thus, NSE and CgA also have prognostic
value. In another study, treatment with the PI3K pathway inhibitor everolimus reduced
CgA (47% of the patients) and NSE (72% of the patients) levels. Patients with an early
decrease (at 4 weeks) in NSE and CgA levels demonstrated improved progression-free
survival (Yao et al., 2011).
Pancreatic polypeptide (PP) has also been combined with CgA for detection of GEPNETs. Although PP by itself is a less sensitive marker than CgA it might have an added
value once used in combination with CgA. On the other hand, PP has also been detected
in patients with other GI tumours and thus might not be specific for PNETs (Panzuto et
al., 2004).
In addition to hormones and peptides, an mRNA analysis has revealed 51 genes which
are significantly upregulated in blood samples of patient with GEP-NETs. This analysis
showed a higher specificity than CgA for tumour and metastasis identification (Modlin
et al., 2013).
In addition to circulating markers, imaging plays a central role in tumour detection,
treatment planning and patient follow up. Computer tomography (CT), magnetic
resonance imaging (MRI) and ultrasound (US) are used for identification of primary
tumours and metastases and are the basis for disease staging. Of these techniques, MRI
has been shown to be the best option for detection of liver metastases. Invasive US
techniques, such as endoscopic US (EUS) and intraoperative US (IOUS), have been
also used for PNET imaging (Bodei et al., 2015).
10

Molecular imaging might be used for functional characterisation of tumours and
metastases, improving staging and helping in therapy selection. In molecular imaging,
radio-labelled tracers are detected with single photon emission computed tomography
(SPECT) or PET. PET in NETs is based on
and

18

68

Ga-labeled SST analogues,

11

C-5-HTP

F-DOPA, with the latter two tracers reflecting metabolical activity of tumours.

SPECT, for example with

111

In-pentetreotide, might be helpful for characterisation of

the SSTR status of NETs, but generally has lower resolution as compared to MRI and
CT. In order to combine functional and structural imaging, hybrid imaging techniques
such as SPECT/CT and PET/CT has been recently developed (Bodei et al., 2015).

1.2.4 Hereditary diseases associated with PNETs
In most cases, PNETs develop sporadically. However, 10% of PNETs can be associated
with rare heritable diseases. The most common of these is multiple endocrine neoplasia
type 1 (MEN1), which is caused by the loss of function of MEN1 in the germline, and
20-70% of MEN1 patients develop PNETs. In the von Hippel-Lindau disease (VHL)
non-functioning PNETs develop in less than 20% of patients. Neurofibromatosis type 1
(NF1), also known as Recklinghausen’s disease, is also a hereditary disease,
accompanied by PNETs in ca 10% of cases. Tuberous sclerosis complex (TSC) is
another hereditary disease where development of PNETs has been observed in less than
1% of patients (de Wilde et al., 2012).

1.2.5 Current treatments
Surgery is currently the only option when it comes to tumour removal. Patients who
underwent removal of the primary tumour with or without metastases had been shown
to have an increase survival rate as compared to patients who did not have surgery
(Keutgen et al., 2016). The surgical procedures for primary PNETs include total-, distalor median pancreatectomy (Sallinen et al., 2015). Total pancreatectomy is the removal
of the entire pancreas. Removal of the pancreatic parenchyma disturbs the glucose
homeostasis and can cause diabetes. In an attempt to prevent diabetes after pancreatic
surgery, new islets are transplanted in the patients. Transplantation is often done in the
liver because its vessels are relatively easy to access (Parks & Routt, 2015). In distaland median pancreatectomy, only a part of the pancreas is removed (Kleeff et al., 2007;
Kishore et al., 2016). When the tumour cannot be removed surgically, the patients are
started on therapy to control tumour progression and to minimise the symptoms from
hormone overproduction. Endogenous somatostatin has a very short half-life (less than
11

3 minutes), which limits its therapeutic utility and thus, synthetic analogues of SSTR are
mostly used, such as octreotide, lanreotide and pasireotide. SST analogues have varying
affinities to different SSTR subtypes, for example octreotide and lanreotide bind mainly
to SSTR2 and SSTR5 (Theodoropoulou & Stalla, 2013; Qian et al., 2017).
As said earlier, PI3K pathway, which is important for survival, cell growth, protein
synthesis and proliferation, is frequently deregulated in NETs and is thus targeted
pharmacologically. One example of targeted therapy for PI3K is Everolimus, a
rapamycin analogue. Everolimus is one of the two drugs, which have been approved by
the European Medicines Agency (EMA) and the US Food and Drug Administration
(FDA) for advanced and metastatic PNETs, or tumours, which cannot be removed by
surgery. The PI3K pathway can also be targeted by drugs, which compete with ATP by
binding to the kinase pocket of mTOR. The drugs then reduce the kinase activity of
mTOR complex 1 (mTORC) and mTORC2. Examples of such compounds are
AZD2014 and OSI-027 (Vandamme et al., 2016).
The second drug, approved by the EMA and FDA, is sunitinib, which inhibits receptor
tyrosine kinases in PNETs. Sunitinib targets vascular endothelial growth factor receptor
(VEGFR), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) and
stem cell factor receptor c-Kit (Raymond et al., 2011).
PNETs (grade I and II) and other NETs, which cannot be removed through surgery, can
also be treated with temozolomide. Temozolomide is an alkylating agent, which
methylates guanines and induces apoptosis. Temozolomide can be used alone or in
combination with other drugs, such as capecitabine (CAPTEM regimen), which causes
DNA damage. The drawback of CAPTEM is toxicity, which however has been
tolerated by most patients. The toxic effects include nausea, hand-foot syndrome
(swelling and pain in palms and soles) or low thrombocyte and lymphocyte levels
(Chauhan et al., 2018; Ramirez et al., 2016).

12

1.3 Somatostatin and somatostatin receptors
SST was discovered in 1968 by Ladislav Krulich in the search of pituitary growth
hormone-releasing factors. Andrew Schally and Roger Guillemin for the first time
extracted somatostatin from sheep hypotalami in 1973 and also sequenced and
synthesised the hormone. Schally and Guillemin were awarded the Nobel prize in
medicine and physiology in 1977 for their studies. In 1974 somatostatin was also found
to be produced by pancreatic δ-cells in different animals (Trofimiuk-Müldner &
Hubalewska-Dydejczyk, 2015).

Figure 4: Somatostatin biogenesis: the precursor peptide preprosomatostatin is cleaved into
prosomatostatin, Prosomatostatin is further cleaved into two functional proteins, SST-14 and -28
(Dasgupta 2004).

SST is an evolutionary conserved peptide, which exists in two forms, SST-14 and SST28. The two forms are generated from the prosomatostatin, which is cleaved to 14
amino acids long SST-14 and 28 amino acids long SST-28 (figure 4). SST is secreted to
the extracellular environment in response to nutrients, hormones and neurotransmitters.
In the extracellular environment SST activates intracellular signalling pathways through
SSTRs. Both SST-28 and SST-14 have high affinity to all SSTR subtypes, however
SST-28 is more selective towards SSTR5.
Activation of SSTRs regulates hormonal levels by inhibiting hormone secretion and
proliferation.

SSTRs

are

G-protein

coupled

receptors

(GPCR)

with

seven

transmembrane domains. Five subtypes of SSTRs, SSTR1-5, have been characterised in
humans. All SSTRs, apart from SSTR2, are encoded by intronless genes. After
transcription, SSTR2 mRNA can undergo alternative splicing and yield two isoforms,
SSTR2A and SSTR2B (Theodoropoulou & Stalla, 2013). In addition, two splice

13

variants of SSTR5 have also been described, SSTR5TMD4 and SSTR5TMD5, which
contain 4 and 5 transmembrane domains instead of 7 (Sampedro-Núñez et al., 2016).

1.3.1 SSTR molecular signalling
SST binding to SSTRs activates trimeric guanine nucleotide binding proteins (Gproteins) and affects several intracellular signalling pathways (figure 5). All five
subtypes of SSTRs are coupled to an adenylyl cyclase-inhibiting Gαi protein
(Theodoropoulou & Stalla, 2013). Adenylyl cyclase catalyses production of the second
messenger cAMP from ATP. cAMP activates the protein kinase A (PKA), which
phosphorylates target proteins, such as the transcription factor cAMP response element
binding (CREB) protein. Phosphorylation of CREB induces transcription of CREB
target genes, such as SST, dual specificity phosphatase 1 (DUSP1) and the
corticotrophin-releasing factor urocortin (UCN). In addition to PKA activation, the
increase of intracellular cAMP levels has been shown to promote exocytosis and Ca2+
influx (Ämmälä et al., 1993; Conkright et al., 2003; Tian et al., 2011).

Figure 5: SSTR pathways. Activation of all SSTR subtypes inhibits cAMP pathway, which results in
reduction of hormone secretion. Other pathways which are activated (open arrowheads) or inhibited
(blunt arrowheads) by the different SSTR subtypes include PKC, MAPK, PI3K, NOS and intrinsic
apoptosis signalling pathways. Arrows with dashed lines mean an indirect effect (Theodoropoulou &
Stalla, 2013).

All SSTR subtypes can also activate or inactivate other signalling pathways. In addition
to cAMP, SSTRs regulate exocytosis through Ca2+ signalling. SSTR activation causes
opening of K+ channels and results in hyperpolarisation of the cell. The
hyperpolarisation inhibits voltage-gated Ca2+ channels and thus reduces Ca2+ influx to
14

the cytosol, which in turn inhibits exocytosis. K+ channels are mostly activated by
SSTR2 and SSTR4, and, to a lesser extent, by SSTR1. Hyperpolarisation through
SSTR5 has an inhibiting effect on Ca2+ channels. The intracellular Ca2+ levels can also
be upregulated by SSTR2 and SSTR5 by activation of the phospholipase C (PLC)
pathway. Activation of PLC induces cleavage of phosphatidylinositol 4,5-biphosphate
(PIP2) to inositol 1,4,5-triphosphate (IP3), which opens Ca2+ channels in the
endoplasmic reticulum (ER), and to diacylglycerol (DAG). DAG and Ca2+ ions, together
activate protein kinase C (PKC). PKC is also directly activated by SSTR4 and
positively regulates the mitogen-activated protein kinase (MAPK) pathway. Activation
of the MAPK pathway through SSTR4 induces proliferation via phosphorylation and
activation of the signal transducer and activator of transcription-3 (STAT3)
(Theodoropoulou & Stalla, 2013). The MAPK pathway is also activated through
SSTR1, which upregulates the cyclin kinase inhibitor p21 and inhibits cell cycle (Florio
et al., 2000). Activation of SSTR2 and SSTR5 also inhibits MAPK pathway by
inhibiting phosphorylation of the MAP kinase Erk1/2 (Li et al., 2016). Cell survival and
proliferation is also regulated through the PI3K pathway, which can be activated by
SSTR1 and SSTR4. SSTR2 has been shown to both inhibit and activate the PI3K
pathway. Finally, proliferation can be inhibited by SSTR1, SSTR2, SSTR3 and SSTR5
through inactivation of the nitric oxide synthase (NOS) (Theodoropoulou & Stalla,
2013; Pedraza-Arévalo et al., 2017). The activation of SSTR2 and SSTR3 has been
shown to induce apoptosis. Activation of SSTR3 induces upregulation of p53 and proapoptotic protein Bax. Activation of SSTR2 has been shown to induce apoptosis in
breast cancer cells by recruiting the protein-tyrosine phosphatase (PTP) SHP-1 to the
plasma membrane. SHP-1 could activate the extrinsic apoptotic pathway and in SHP-1
defective mice, dysregulated apoptosis has been reported (Sharma et al., 1996;
Thangaraju et al., 1999).

1.3.2 Regulation of SSTR signalling
GPCR signalling can be modulated through receptor binding proteins. In neurons the Cterminus of SSTR2 has been shown to interact with somatostatin interacting protein
(SSTRIP) and cortactin-binding protein 1 (CortBP1) through a PDZ-domain. Both
SSTRIP and CortBP1 can interact with the cortical actin by binding to the actin binding
protein cortactin, which could result in localisation of the receptor to specific sites in the
cell (Zitzer et al., 1999a, 1999b). In SSTR3 the PDZ-domain has been shown to interact
15

with multiple PDZ domain protein (MUPP1), which is a tight junction protein that
affects the permeability of tight junctions (Liew et al., 2008).
The number of SSTRs can be regulated through endocytosis and SSTR endocytosis is
normally triggered upon ligand binding. SSTR internalisation rates vary across species,
cell types and receptor subtypes. Many studies have shown that SSTRs 2, 3 and 5 are
more effectively internalised than SSTR1 and SSTR4. The internalised ligand-receptor
complexes localise in endosomes, where the ligand is most likely released from the
receptor (Stroh et al., 2000). SSTR signalling can also be regulated through hetero- or
homodimerisation of receptors. A study in a hamster ovary K1 (CHO-K1) cell-line has
shown that activation of SSTR5 with SST-14 dose-dependently changed the receptor`s
affinity to ligands and the receptor homodimerisation rate. SSTR5 was unable to form
heterodimers when co-expressed with SSTR4. However, co-expression of SSTR5 and
SSTR1 resulted in heterodimerisation and internalisation of the heterodimer, which
indicates that the dimerisation is receptor-specific (Rocheville et al., 2000).

1.3.3 Somatostatin receptors in pancreatic neuroendocrine tumours
Activation of SSTRs in PNETs inhibits hormone secretion by tumour cells and their
proliferation. The islet cells of the pancreas have been reported to express of SSTR1,
SSTR2, SSTR3 and SSTR5. SSTR4 is expressed in the exocrine acinar cells, which
surround the islets. SSTR3 and SSTR4 have mostly cytoplasmic expression, whereas
other SSTR subtypes were found both in the cytoplasm and plasma membrane (Schmid
et al., 2012). In PNETs the expression of all five SSTRs have been observed. Of the five
SSTRs, SSTR1 is overexpressed in 47% of PNETs and SSTR2 in 51% of the tumours
(Qian et al., 2017). Poorly differentiated PNECs have shown a weaker staining for
SSTR1, SSTR2 and SSTR4 than well-differentiated PNETs. Contrary to this, SSTR5
had higher expression in PNEC than in well-differentiated PNETs. No differences in
SSTR expression have been observed between primary tumour and metastasis (Schmid
et al., 2012). SSTR2a expression in well-differentiated PNETs has been positively
correlated with improved overall survival in patients (Mehta et al., 2015).

16

1.4 Overview of Notch signalling pathway
The Notch receptor was discovered in 1917 by T. H. Morgan when he detected that a
mutation in the X chromosome resulted in notched wing ends in the Drosophila
(Morgan, 1917). By the late 1980s, the importance and function of Notch pathway in
normal development and certain pathological states have become generally accepted
(Penton et al., 2012). The Notch receptors and ligands are evolutionary conserved and
interact through cell-cell contacts (Gomez-Lamarca et al., 2018). In mammals the signal
is mediated through four transmembrane Notch receptors, Notch1-4. The receptors
interact with five transmembrane ligands: Jagged 1 (JAG), JAG2, Delta-like ligand 1
(DLL), DLL3 and DLL4 (Figure 6). Notch signalling is important for cell fate decisions
and it regulates apoptosis, proliferation, growth, survival and differentiation (Hai et al.,
2018; Nandagopal et al., 2018). Mutations in the Notch signalling pathway can cause
various diseases and developmental disorders. Mutations in JAG1 and Notch2 cause
Alagille syndrome that is principally manifested with liver disease with deregulated
development of the intrahepatic bile ducts. Notch2 mutations have also been detected in
Hajdu-Cheney syndrome, which causes osteoporosis and renal cysts. Mutations in JAG1
and Notch1 have been linked to cardiac disorders such as pulmonary stenosis, tetralogy
of Fallot (TOF) and aortic valve deformities. Mutations in Notch3 cause cerebral
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL), manifesting with early vascular dementia (Penton et al., 2012).

1.4.1 Structure of Notch receptors and ligands
The N-terminus extracellular domains of the Notch receptors (NECDs) have 29-36
epidermal growth factor-like (EGF) repeats and of these the EGF11 and 12 are
important for ligand binding. Following the EGF-repeats is the negative regulatory
region (NRR), which consists of three Lin 12 and Notch repeats (LNR) and a
heterodimerisation domain (HD) (figure 6). The NRR is important for inhibiting the
second cleavage of Notch and prevents signalling when the ligand is absent. The Notch
intracellular domain (NICD) consists of a RBPJ-associated molecule (RAM) domain
and ankyrin (ANK) repeats with three nuclear localisation signals (NLS). The RAM and
ANK interact with the CSL in the nucleus and activate transcription of target genes
(Kovall et al., 2017). Following ANK repeats, the NICD contains a Notch cytokine
response (NCR) domain, which can affect localisation of the NICD and modulates
Notch signalling in response to cytokines (Bigas et al., 1998). The transcriptional
17

activation domain (TAD) is important for the activation of transcription by recruiting
acetyltransferases. Finally, a Pro/Glu/Ser/Thr-rich domain (PEST) in the C-terminus of
the receptor regulates degradation of the NICD (Kovall et al., 2017; Fryer et al., 2002).
Before the receptors are transported to the plasma membrane, they are processed in the
Golgi apparatus. The 300 kDa Notch precursor is cleaved into a heterodimeric receptor
by a Furin-dependent protease (S1 cleavage). The two heterodimers stay bound with a
non-covalent bond. The receptors are also known to undergo several post-translational
modifications (PTM), such as O-linked glucosylation, phosphorylation, ubiquitination
and methylation. Receptors are then transported to the plasma membrane, where they
can interact with ligands (Logeat et al., 1998; Fryer et al., 2004; Hein et al., 2015).

Figure 6: Structure of the Notch receptors (left) and ligands (right). The receptors and ligands have
an extracellular domain (NECD) and an intracellular domain (NICD). The NECD in all receptors consists
of epidermal growth factor (EGF)-like repeats, which are important for receptor-ligand interactions and
an NRR, which prevents signal activation in the absence of ligands. The NICD contains RBPJ-associated
molecule (RAM), ankyrin (ANK), nuclear localisation signals (NLS), Notch cytokine response domain
(NCR), transcriptional activation domain (TAD and Pro/Glu/Ser/Thr-rich domain (PEST). In addition, the
Notch receptors have three cleavage sites (S1-3) close to the transmembrane domain, which are important
for receptor activation. The ECDs of the Notch ligands contain a module at the N-terminus of Notch
ligands (MNNL), Delta/Serrate ligand (DSL) domain and EGF-repeats, which interact with the Notch
receptors. The Jagged (JAG) ligands differ from Delta-like ligands (DLLs) by having a Cys-rich domain
on the ECD, close to the plasma membrane. The ICD of the ligands consist of a conserved amino acid
sequence and some ligands also have a PDZ-binding domain (Arruga et al., 2018).

The Notch ligands JAG1 and JAG2 belong to the Jagged family of Serrate homologs,
whereas the DLL1, DLL3 and DLL4 belong to the Delta-like family (figure 6). The Nterminus of the ligands` extracellular domains contains a module at the N-terminus of
Notch ligands (MNNL) and a conserved Delta/Serrate ligand (DSL) domain, which
interact with the Notch receptors. MNNL and DSL are followed by 6-16 EGF-like
repeats. (Kovall et al., 2017). The JAG ligands have a conserved Cys-rich domain after

18

the EGF repeats, which is not found in the DLLs. The intracellular domain of the
ligands represents a short conserved amino acid sequence (Pintar et al., 2007).

1.4.2 Notch signalling pathway
Notch pathway is a conserved cell-to-cell signalling mechanism, where Notch receptors
on so-called signal receiving cells are activated by Notch ligands on signal sending
cells. This mode of interaction is called trans-activation. Notch pathway can also be
activated or inhibited through cis-interactions, where the interacting receptors and
ligands are on the same cell (Kovall et al., 2017; Nandagopal et al., 2019). Whether
cells serve as Notch signal-sending or signal-receiving cells, is determined by the
number of receptors and ligands on the cells. In signal sending cells, the number of
ligands is higher than the number of receptors. A hybrid state where cells can have an
equal number of receptors and ligands could also exist (Boareto et al., 2015). Here, the
activation of the Notch pathway through trans-activation is explained (figure 7).
Notch signalling is initiated through the interactions between the EGF-repeats of
extracellular domains of receptors and ligands. However, a receptor-ligand interaction is
not enough, and a physical force is required to activate the receptor. This force is
generated through the endocytosis of Notch ligands. The ligands at the plasma
membrane are marked for endocytosis by the E3 ubiquitination ligase Mindbomb (Mib)
and are recognised by the adaptor protein epsin. Epsin targets the ligands to clathrinmediated endocytosis in a signal-sending cell (Langridge & Struhl, 2017). The ligand
endocytosis generates a force that opens the NRR in the Notch receptor and reveals a
cleavage site, which is recognised and cleaved by a disintegrin and metalloprotease
(ADAM, S2 cleavage) (Kovall et al., 2017). The S2 cleavage produces an
intermembrane Notch extracellular truncation (NEXT) in a signal-receiving cell, and the
NECD and ligand are trans-endocytosed by a signal-sending cell. The production of
NEXT allows for the third cleavage (S3) to happen (Mumm et al., 2000; Langridge &
Struhl, 2017).

19

Figure 7: The canonical Notch signalling pathway. The Notch receptor is first processed in the Golgi
by Furin-mediated cleavage and O-linked glycosylation. The receptor is then transported to the plasma
membrane, where the extracellular domain of the Notch receptor can interact with the Notch ligands
Jagged or Delta-like ligand on a signal sending cell. Endocytosis of the receptor-ligand complex unfolds
the NRR and exposes a cleavage site, which is cleaved by ADAM. The third cleavage of the Notch
receptor by γ-secretase releases the NICD. The NICD is further transported to the nucleus, where it binds
to CSL, recruits transcription activators and induces transcription of Notch target genes (MacGoran et al.,
2018).

The S3 cleavage is catalysed by the transmembrane protein complex γ-secretase, which
consists of the catalytic domain presenilin1 (PS1), Aph-1a that is important for complex
assembly, Pen-2 that is required for PS1 maturation, and Nicastrin, which stabilises the
complex (Kovall et al., 2017). The cleavage of NEXT releases the NICD from the
plasma membrane to the cytosol where it is translocated to the nucleus by three nuclear
localisation signals. If NEXT production is inhibited, less NICD is produced and
inhibition of the S3 cleavage results in NEXT accumulation in the plasma membrane
(Mumm et al., 2000; Kovall et al., 2017). In the nucleus, NICD binds to the
recombining binding protein suppressor of hairless (RBPJ), also commonly known as
CSL (CBF1/RBPJ, Su(H) and Lag-1). Without NICD, CSL is associated with certain
co-repressors, such as Hairless (Hs) and binds to DNA transiently, preventing efficient
20

transcription of Notch target genes. Upon interaction with NICD, CSL recruitment to
DNA increases and CSL stays bound to DNA for a longer time period. The NICD-CSL
complex recruits the co-activator Mastermind-like (MAML) and MAML recruits the
acetyltransferases p300/CREB-binding protein (CBP), p300/CBP associated factor
(PCAF) and GCN5, making the transcription site more accessible for the RNA
polymerase II (Popko-Scibor et al., 2011; Gomez-Lamarca et al., 2018). NICD, CSL
and co-activators induce transcription of the basic helix-loop-helix (bHLH) genes HEY
and hairy and enhancer of split 1 (HES1), which in turn repress several target genes.
NICD-CSL has also been shown to directly activate c-MYC. The NICD-CSL also
induces transcription of Notch-regulated ankyrin repeat protein (Nrarp), which binds to
the NICD and negatively regulates the signalling (Pirot et al., 2004; Palomero et al.,
2006).
Though the canonical Notch signalling appears quite straightforward, Notch pathway is
context-dependent and can crosstalk with other signalling pathways (non-canonical
signalling), such as NF-κB (Hai et al., 2018), p53 (Yang et al., 2004) and Wnt (Foltz et
al., 2002). Notch signalling can also be receptor-independent. There is some evidence of
cleavage of the intracellular domain of DLL1 and JAG2 close to the transmembrane
domain by γ-secretase. As the intracellular domains of JAG2 and DLL1 have also been
observed in the cytosol, it has been suggested that the cleavage event could have a
transcriptional effect in a cell (Six et al., 2003; Ikeuchi & Sisodia, 2003). In addition,
Notch-independent signalling could occur in the plasma membrane, since JAG1, DLL1
and DLL4 may interact with other proteins through a PDZ-domain. JAG1, DLL1 and
DLL3 also contain SH2 domains, which can function as docking sites for other proteins
(Pintar et al., 2007).

1.4.3 Regulation of Notch signalling
The number of Notch receptors and ligands in the plasma membrane affects the strength
of signal activation and is regulated by endocytosis. Notch receptors and ligands are
continuously endocytosed and localised to endosomes. Endosomes can further fuse with
lysosomes resulting in degradation of the receptors or ligands. Endosomes can also be
recycled back to the plasma membrane, which affects the number of Notch ligands and
receptors on the plasma membrane. Mutations in the endosomal pathway have been
shown to affect the localisation of Notch receptors. Moreover, Notch activity in
endocytic compartments has been also described. It has been suggested that Notch
21

signalling in endosomes could be ligand-independent, and perhaps mediated by γsecretase activity (Vaccari et al., 2008).
Notch signalling is also regulated through post-translational modifications of the
extracellular- and intracellular domains of Notch receptors. The NECD can be modified
in the ER by O-glycosyltransferases, which add O-glycans to specific serine or
threonine residues in the EGF repeats. The NECD can be O-glycosylated by different
types of O-glycans such as O-fucose, O-glucose, O-GlcNAc and O-GalNAc (figure 8)
(Takeuchi et al., 2017; Steentoft et al., 2013). For example, addition of O-fucose to
NECD is catalysed by protein O-fucosyltransferase 1 (POFUT1) in the ER and has been
shown to affect the receptor-ligand interaction. High O-fucose levels increase NotchJAG interactions and inhibit Notch-DLL interactions. In addition, O-fucose can be
elongated by Fringe enzymes, which add GlcNAc to EGF-bound fucose. Elongation by
Fringe causes an opposite effect on Jagged and Delta-like ligands by increasing NotchDLL interactions and inhibiting Notch-JAG binding (Okajima et al., 2003).

Figure 8: Predicted O-Glucosylation sites in Drosophila NECD. O-glycosyltransferases recognise
specific regions in the EGF repeats of NECD and add O-fucose (red), O-glucose (blue) and O-GlcNAc
(green). Image modified from Harvey et al., 2016.

Phosphorylation can have different effects on NICD. To terminate Notch signalling the
NICD domains TAD and PEST can be phosphorylated by cyclin-dependent kinase 8
(CDK8). The phosphorylated site is recognised by Fbw7 ubiquitin ligase, which
ubiquitinates the NICD in the nucleus and targets it for degradation in proteasomes. In
addition, the NICD can be ubiquitinated by Itch, which results in degradation of the
cytoplasmic NICD (Fryer et al., 2004). The protein kinase C iota (PKCζ)
phosphorylates the ICD of membrane-bound Notch and affects the localisation of
receptors. When Notch is phosphorylated in its active form, the receptor is
transferred from endosomes to the nucleus. When the inactive form of Notch is
phosphorylated by PKCζ, Notch receptors are endocytosed (Sjöqvist et al., 2014).
22

Phosphorylation of N1ICD by the glycogen synthetase kinase-3β (GSK-3β) has been
shown to reduce the proteolysis of the NICD (Foltz et al., 2002). Transcriptional
activity of NICD can also be regulated by histone acetyltransferases (HAT), which
acetylate specific lysins of NICD. Acetylation of NICD lysins results in different
functional outcomes. In Notch1, acetylation by p300 has been shown to reduce
degradation of the NICD by blocking CDK8-mediated phosphorylation, which marks
NICD for degradation. When Notch1 is acetylated by TIP60, the Notch-CSL interaction
becomes weaker and NICD is released from CSL (Popko-Scibor et al., 2011). Notch
transcription is also regulated by the coactivator-associated arginine methyltransferase
CARM1, which methylates arginine residues of NICD. Five conserved methylation
sites have been described in Notch1 TAD domain, but not in the other receptors.
Methylation has been shown to accelerate proteasomal degradation of Notch1 ICD
(Hein et al., 2015).
The ANK repeats 1-7 of Notch receptors 1-3 have two conserved Asp sites, which can
be hydroxylated during hypoxia by factor-inhibiting HIF-1α (FIH-1). The hydroxylation
regulates transcription of Notch target genes and mutations in the Asp sites reduce
Notch activity. Negative regulation of Notch through hydroxylation has been shown to
affect differentiation of myoblasts and neuronal cells. ICD of Notch4 contains only one
the two Asp sites but has not been shown to be hydroxylated (Zheng et al., 2008).
Different ligand-receptor interactions induce signal outputs of varying strength, which
drive different fates in signal receiving cells. In the thymus Notch signalling regulates
the gradual development of T-cells. Notch signalling determines if the cells express γδor αβ-receptor, and the receptor type, which becomes expressed depends on whether
Notch1 and -3 interact with JAG1 or JAG2. When JAG2 interacts with the two
receptors the signal is stronger, and cells start to express the γδ-receptor. JAG1 induces
a weaker signal, which promotes differentiation to αβ-receptor expressing cells, since
the weaker signal cannot induce the expression of Notch target genes (Van de Walle et
al., 2013). In the myoblast cell line C2C12, activation of Notch by different ligands
have been shown to induce different gene expression patterns. DLL1-Notch1
interactions have been shown to produce pulses in the Notch target gene expressions,
whereas DLL4-Notch1 interactions induced more sustained and continuous gene
expression patterns in the Notch-signal receiving cells (Nandagopal et al., 2018).

23

1.4.4 The role of Notch in development of pancreatic endocrine cells and
pancreatic neuroendocrine tumours
The early development of the pancreas starts from the formation of pancreatic buds,
which further develop into the pancreatic ducts, endocrine- and exocrine cells. Notch1
becomes expressed in the pancreatic epithelium during embryonic day 9.5 (E9.5). When
the pancreatic bud branches during E11.5, Notch2 becomes also expressed in the
epithelium. Later, Notch2 becomes restricted to the ductal cells. Notch1 is localised in
acinar- (exocrine) and epithelial cells. Notch3 and Notch4 expressed in the pancreatic
mesenchyme cells and later (E15.5) in the endothelial cells (Lammert et al., 2000;
Golson et al., 2009).
In the pancreas Notch1 signalling is important in the development of duct-, endocrineand exocrine cells. Once the dorsal pancreatic bud has been formed, Notch signalling is
activated in the bud by DLL1, JAG1 and JAG2. DLL1 is highly expressed in the
pancreas on E9.0 and activation of Notch1 signalling by DLL1 causes transcriptional
repression of the transcription factor neurogenin3 (Ngn3). Ngn3 is needed for
commitment to neuroendocrine precursor cells. If Ngn3 is lost, endocrine cells are not
formed in the pancreas, whereas loss of DLL1 or RBPJ-κ results in overproduction of
endocrine cells. In order to differentiate to mature neuroendocrine cells, inhibition of
Notch signalling is required in the neuroendocrine precursor cells. It has been proposed
that when Notch is glycosylated by Manic Fringe, JAG1 exerts an inhibitory effect on
Notch signalling and competes with DLL1 since JAG1 is expressed later than DLL1.
Inhibition of Notch1 results in Ngn3 expression and the precursor cells mature into
endocrine cells. The α-cells develop during E9.5, β-cells at circa E13.5, followed by
development of the exocrine cells (Murtaugh et al., 2003; Golson et al., 2009).
Notch can function as a tumour suppressor or as an oncogene. For example, in some Tcell acute lymphoblastic leukaemia (T-ALL) cases Notch1 acts as an oncogene (Weng
et al., 2004), while in squamous cell carcinoma (SCC) Notch acts as a tumour
suppressor (Proweller et al., 2006). Since low Notch activity has been described in most
PNETs, Notch is believed to function as a tumour suppressor in these tumours
(Mohammed et al., 2011). In one immunohistochemical study, 34% of PNET samples
showed Notch1 expression and 10% Hes1 expression (Wang et al., 2013). Histone
deacetylase inhibitors such as valproic acid, bis-hydroxamic acid (SBHA), as well as
polyphenolic compounds such as trans-resveratrol (RSVT), chrysin, genistein and
24

thiocoraline have been shown to increase Notch transcription and thus could be used to
increase Notch signalling in PNETs (Adler et al., 2008; LaFoya et al., 2019). In the
pancreatic neuroendocrine tumour cell line BON1, treatment with valproic acid and
thiocoraline increased Notch1 mRNA levels, inhibited the cell cycle, and reduced levels
of NET marker CgA. Furthermore, valproic acid increased SSTR2 expression and
reduced the expression of the other SSTR subtypes (Wyche et al., 2014; Sun et al.,
2015). However, in a small phase II trial valproic acid did not reduce growth of
metastatic PNETs and carcinoids, although Notch1 mRNA expression in tumours
increased 10-fold on average and reduction of CgA levels was achieved (Mohammed et
al., 2011). Introduction of NICD in BON1 cells has also reduced ASCL1 mRNA levels,
serotonin secretion, NSE and CgA expression, and inhibited the cell cycle (Nakakura et
al., 2005).

25

2 Previous research, hypothesis and aims
Since PNETs are rare, very little is known about their molecular mechanisms. The only
treatment to remove the tumour is surgery, but this is rarely possible due to late
diagnosis and advanced stage of the disease. Thus, new approaches to treatment,
specifically for patients with metastasis, are urgently needed. One possibility could be
to target Notch pathway. Notch pathway is believed to act as a tumour suppressor in
PNETs. However, its function is not well understood at molecular level. In my thesis I
will study whether there might be a connection between Notch and SSTRs.
Earlier, our research group has generated genetically-engineered BON1 cells with
different SSTR2 and -5 expression. When these cells were implanted to
immunodeficient mice in a small pilot experiment, SSTR2 and SSTR5 double knockout
(SSTR2/5 KO) BON1 yielded larger and highly vascular tumours in comparison to
BON1 cells with endogenous SSTR expression (BON1 WT) and BON1 with SSTR5
overexpression (SSTR5 OE) (figure 9A). Western blot with the lysates of the above cell
lines also revealed that the BON1 SSTR2/5 KO cells expressed high levels of JAG1
(figure 9B) whereas JAG1 seemed absent in the BON1 SSTR5 OE cells.

Figure 9: Tumour sizes and JAG1 levels in BON1 cells. (A) BON1 WT, SSTR5 OE and SSTR2/5 KO
cells were transplanted to immunodeficient mice. After 3 weeks, BON1 SSTR2/5 KO cells had produced
much bigger tumours as compared to BON1 WT and SSTR5 OE cells. n=4 (B) JAG1 expression in
BON1 WT, SSTR5 OE and SSTR2/5 KO cells was assessed with western blot. Increased JAG1 was
detected in BON1 SSTR2/5 KO cells. In BON1 SSTR5 OE cells JAG1 seemed absent. Hsc70 was used
as a loading control.

26

Figure 10: Investigational JAG1 antibody inhibits growth of BON1 SSTR5 KO xenografts. BON1
SSTR5 KO cells produced bigger tumours than BON1 WT. Xenografts were treated with JAG1inhibiting antibody, which reduced the tumour size in SSTR5 KO-derived tumours but did not affect
tumours of BON1 WT cells.

In a second in vivo experiment, mice grafted with BON1 SSTR5 KO cells yielded
bigger tumours than BON1 WT cells (figure 10). Moreover, when the mice were
administered with an investigational JAG1 antibody, only BON1 SSTR5 KO xenografts
responded to the treatment. These results further support a connection between
JAG1/Notch and SSTR.
Interestingly, in one earlier study upregulation of Notch1 increased SSTR1 and -2
mRNA levels and induced cell cycle arrest in a model of cervical cancer. Notch1
upregulation also affected cAMP, MAPK, PKC and PI3K pathways (Franko-Tobin et
al., 2012).
Thus, the main hypotheses of this project are that 1) there is a functional link between
SSTRs and Notch signalling in PNETs, which is possibly mediated through JAG1 and
2) Notch-SSTR crosstalk is relevant for PNET development and progression and could
be exploited therapeutically.
Main aims:
Aim 1: To study how expression levels of SSTR2 and SSTR5 affect cAMP signalling
pathway in BON1 cells
Aim 2: To study whether expression levels of SSTR2 and SSTR5 affect Notch
signalling in BON1 cells
Aim 3: To study whether JAG1 could be targeted in PNETs
27

3 Materials and methods
3.1 Cell culture
A human PNET cell line BON1, which originates from a PNET metastasis to a lymph
node, was used for the experiments. To study the interplay between Notch and SSTRs, I
used the following cell types: BON1 with endogenous SSTR expression (WT), BON1
with SSTR2 loss (SSTR2 KO), BON1 with SSTR5 loss (SSTR5 KO), BON1 with
SSTR5 overexpression (SSTR5 OE) and BON1, which had both SSTR2 and SSTR5
knocked out (SSTR2/5 KO). SSTR-KO cells were generated via CRISPR-Cas9 method
by V. Paramonov, whilst SSTR5 OE cells were stable transfects (transfection with
SSTR5-endcoding plasmid with subsequent selection of stable clones).
BON1 cells were cultured in DMEM (Sigma) and F12K Nut mix (Gibco) (1:1 ratio),
supplemented with 10% FBS (Biowest), 100 U/ml penicillin and 100 µg/ml
streptomycin.
In addition, I also used human embryonic kidney 293 cells (HEK 293), which express a
full-length Notch1 (FLN1) receptor and mouse embryonic fibroblast 3T3 cells with
JAG1 overexpression. The HEK FLN1 cells were cultured in DMEM, supplemented
with 10% FBS, 2 Mm L-Glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin.
3T3 JAG1 cells were cultured in DMEM with 10% FBS, 2 Mm L-Glutamine and 0.5
µg/ml puromycin.
All cell types were incubated in 37 °C and 5% CO2. Detachment of cells from cell
culture plates was done by removing the old medium with suction (Vacusafe; Integra),
with subsequent wash with 1x PBS (Biowest). Trypsin (0.25% EDTA in HBSS;
Biowest) was then added to the plates and the cells were incubated for 1-10 min at 37
°C until they were completely detached from the plate.

28

3.2 Western blot
3.2.1 Lysate preparation
Western blot was used in order to study levels of the proteins of interest in BON1 cells.
To detect the target protein, all proteins and lipids needed to be solubilised first into a
heterogenous mix. Here, a protocol for cells growing in a 6 well plate that I used is
specified. Adherent cells, grown in culture plates to 70-100% confluency, were put on
ice. Medium was removed with suction and cells washed with 1x PBS. PBS was
removed by suction and 100 µl of 3x Laemmli was added to the cells. The Laemmli
buffer contained 3% β-mercaptoethanol to break disulphide bonds and 3% SDS to
remove protein charge. Cells were scraped from plates and transferred to 1.5 ml
Eppendorf tubes. Samples were then boiled on a thermoblock at 95 °C for 5-10 min.
Samples were then cooled down to RT and vortexed before protein quantification.
Lysates were stored in -20 °C.

3.2.2 Protein quantitation with Pierce 660 nm assay
To measure the total amount of protein in lysates, the Pierce 660 nm assay (Thermo
Fisher) was used since the assay is compatible with Laemmli. The Pierce 660 assay is
based on a dye-metal complex, which recognises and binds to certain amino acids in
proteins. When the dye-metal complex is bound to proteins, the absorption maximum of
the dye changes and then the absorption can be measured at 660 nm.
A small amount of lysate was taken for protein measurement and diluted between 1:3
and 1:10 in 3x Laemmli, depending on the protein concentration. The diluted lysates
and a BSA standard were pipetted into a 96 well plate, 10 µl in each well, in triplicates.
One triplicate with only 10 µl 3x Laemmli was also added to measure background
signal. Next, 150 µl of Pierce reagent with Ionic Detergent Compatibility Reagent
(IDCR) was added to each well. The covered plate was incubated for 5 min at RT. The
absorbance of each well was then read at 660 nm on a Hidex plate reader. The protein
yield was further calculated with MS Excel software. The protein concentrations in the
samples were calculated with the help of a standard curve. The standard curve was
created from a set of BSA samples of known concentration.

29

3.2.3 Western blot
Western blot is a method for separation of proteins in polyacrylamide gels, based on
protein size. The gel consists of an upper stacking gel and a lower separating gel. The
stacking gel is more porous and acidic (pH 6.8) than the lower gel and aligns the
proteins before the protein separation is initiated. The separating gel separates the
proteins by their size so that the smallest proteins travel faster and further on the gel,
while bigger proteins lag behind. The unidirectional migration is made possible by
adding SDS to the running buffer and Laemmli lysis buffer, for SDS renders the
proteins negatively-charged. Once all the proteins have a negative charge, they will
migrate towards the positive electrode of the electrophoresis system. If the positive
charge is not removed, the positively and neutrally charged proteins would not migrate
towards the positive electrode and thus, the proteins would separate by the charge and
not the size.
For protein separation, 10-12 µg protein lysates and 5 µl of the marker Precision Plus
Protein Dual Color Standard (Bio-Rad) were loaded onto either in-house casted or precast (prepared by a commercial supplier; 4-20% mini-PROTEAN TGX gels; Bio-rad)
polyacrylamide gels. The gels were placed in an electrophoresis tank, pre-filled with 1x
running buffer containing SDS with a final concentration of 0.1% and 120 V was
applied to the system for 1.5 h to separate the proteins. The proteins were then
transferred from the separating gels to nitrocellulose membranes with pore size of 0.45
µm (GE healthcare, Amersham). For this purpose, a transfer sandwich was constructed
in following order: a cushion, two Whatmann papers, separating gel, nitrocellulose
membrane, two Whatmann papers and a cushion. The sandwich was placed in the
transfer chamber filled with a transfer buffer of 4 °C. Additionally, the transfer chamber
was placed on ice to prevent the system from heating and 100 V was applied to the
transfer system for 1 h. Once the transfer was done the membrane was washed twice
with washing buffer for 5 min. To ensure the balanced loading, REVERT total protein
stain (Li-COR) was applied for 5 min. The stain was then washed twice with REVERT
wash solution for 30 sec and then with MQ water. The membrane was imaged with
ChemiDoc MP imaging system (Biorad) at 700 nm to visualise the bands. The stain was
removed by washing the membrane with REVERT reversal solution for 7 min or until
no total protein stain was detected. Further, the membrane was washed with washing
buffer twice for 5 min. To prevent unspecific antibody binding, the membrane was
30

blocked with 5% milk blocking solution for 1 h following 2x 5 min wash with washing
buffer. The membrane was then incubated for 1 h with primary antibodies, which bind
to proteins of interest. The membrane was washed 2x 5 min wash with washing buffer
to wash away excess antibodies. To be able to visualise the proteins of interest,
horseradish peroxidase (HRP) -conjugated secondary antibodies, which recognise and
bind to the primary antibodies were added to the membrane for 1 h. To wash excess
antibodies, the membrane was rinsed 2x 5 min with washing buffer. The membrane was
then incubated for minimum 10 sec in enhanced chemiluminescence (ECL) solution,
which contained a substrate for HRP enzyme. HRP oxidises its substrate, resulting in
the production of light (Smith et al., 1990). The light intensity from HRP was measured
with the ChemiDoc imaging system (Biorad).

3.3 WST8 assay
NAD+ is a co-factor, which is reduced in the mitochondria to NADH during cellular
respiration. In the presence of NADH, WST8 is reduced to a water-soluble dye, WST8
formazan, which diffuses to the cell culture medium from the cells and produces orange
discoloration (figure 11). The intensity of the orange colour can thus be used as a
measure of the number of viable cells (Chamchoy et al., 2019).

Figure 11: A principle of WST8 assay: in viable cells NAD(P) is reduced to NAD(P)H by the
dehydrogenase enzyme. In presence of NAD(P)H, WST8 dye is reduced to the orange dye formazan,
thus the orange discoloration is proportional to the number of viable cells (Chamchoy et al., 2019; Figure
from Dojindo.com).

To study proliferation rates in BON1 cells under different metabolical conditions,
BON1 cells were plated in a 96 well plate as 6000 cells/well. The cells were cultured in
100 µl medium, containing 10% FBS and 0.2% FBS (starvation). After 48 h, 10 µl of
WST8 reagent (Dojindo) was added to each well to a final concentration of 10%. The

31

plates were then incubated for 2 h in 37 °C and the absorbance at 450 nm was measured
with the Hidex plate reader.

3.4 Reporter assay for Notch activity
3.4.1 Plasmids and transfections
For reporter assays, pGL4 vector 12xCSL-Fluc was transfected to cells together with
SV40-hRluc (the hRluc plasmid were from Promega; 12xCSL construct was a gift from
Prof. Urban Lendahl, KI, Stockholm, Sweden). The 12xCSL-Fluc plasmid has 12xCSL
binding motifs and thus transcription of the firefly luciferase is proportional to Notchdriven transcriptional response. The hRluc, which expresses renilla luciferase from
under a constitutive SV40 promoter, was used as a control. The ratio of 12xCSL-Fluc
and SV40-hRluc plasmids at transfections was 9:1. For a visual transfection efficacy
control, cells were transfected with a plasmid expressing the red fluorescent protein
mCardinal and imaged with EVOS microscope.
BON1 cells were transfected with FugeneHD reagent (Promega), as follows: 0.02 µg/µl
DNA and 3-4 µl fugene per 1 µg of DNA. The transfection mixes were prepared in
Optimem medium (Invitrogen). Xfect (Clontech) reagent was used to transfect HEK
FLN1 cells. The transfection mix for a 6 well plate contained Xfect reaction buffer, 6 µg
plasmid/100 µl transfection mix and 0.3 µl Xfect polymer per 1 µg plasmid. Both
transfection mixes were thoroughly vortexed and then incubated for 10 min before
pipetting into the wells.

3.4.2 Dual-Glo luciferase assay
Reporter assay is a method for measurement of expression of genes of interest. This is
done by introducing a reporter gene, such as luciferase or fluorescent proteins to the
cells. The expression of the reporter gene should reflect the transcription of a gene of
interest. Since different cell types can have varying transcription rates and differ in
terms of transfection efficacy, normalisation for these factors is done by co-transfecting
cells with a control reporter construct, which is continuously expressed and not affected
by the target gene. To measure transcriptional activity of the target protein CSL, I used
the Dual-Glo luciferase system (Promega) where the cells were co-transfected with
12xCSL-Fluc and SV40-hRluc. Therefore, the luminescence signal from 12xCSL-Fluc is
proportional to the transcriptional activity of CSL.

32

Prior to the assay, 75 µl of Dual-Glo firefly luciferase reagent was added to each well in
a 96 well plate. The plates were first incubated for 1 min with shaking, following a 30
min incubation without shaking at RT. The firefly luminescence was read with the
EnSight (Perkin Elmer) plate reader. Next, Stop & Glo reagent was prepared fresh by
adding Stop & Glo substrate 1:100 to Stop & Glo buffer and 75 µl of Stop & Glo
reagent was pipetted to each well. The Stop & Glo reagent quenches the firefly
luminescence and serves as the substrate for Renilla luciferase. The Rluc luminescence
was further measured on the EnSight plate reader.

3.5 Notch activation with ligand peptides
To supplement the reporter assay, described above, I also used plates, which were
coated with JAG1 peptides in order to activate Notch in BON1 cells. The surface of 96well plates were first coated with 50 µg/ml recombinant protein G (Thermo Fisher),
which is an IgG-binding protein from Streptococcus (Fahnestock et al., 1986). The plate
was incubated at RT overnight. On the following day, the wells were washed 3x with
150 µl sterile PBS and blocked with 40 µl 1% BSA in PBS for 1 h. Excess block was
washed away with 3x 150 µl sterile PBS. JAG1 peptides (R&D Systems) were prepared
by diluting the peptides in 0.1% BSA in PBS for peptide concentrations of 0.1 µg/ml,
0.5 µg/ml, 2 µg/ml and 5 µg/ml. The same concentrations of IgG Fc (R&D Systems)
were used for control. Of each peptide concentration, 35 µl was pipetted to the wells
and the plate was incubated for 2 h. After the incubation the wells were washed 2x with
150 µl PBS. Each well was then seeded with 20 000 cells in 80 µl of antibiotic-free
medium. The plate was incubated for 24 h and luciferase activity was then measured
with the Dual-Glo system (as described in section 3.4.2).

33

4 Results
4.1 Profiling BON1 cells for Notch receptors and ligands
Notch receptor and ligand levels in BON1 cells were studied with western blot. For the
western blot experiments BON1 WT, SSTR5 OE and two different SSTR5 KO cells
(clones A11 and C8) were used. Different SSTR5 KO clones were used to verify that
any observed effect is indeed a result of SSTR5 loss and is not a consequence of offtarget events induced in cells during mutagenesis.
Before the final profiling, the function of antibodies were verified with western blot by
using cells with known overexpression or loss of target proteins. The verified
antibodies, which were used in this experiment, were JAG1 28H8 (Cell Signaling),
Notch1 bTan20 (Developmental Studies Hybridoma Bank, University of Iowa) and
Notch3 2889S (Cell Signaling). The Revert 700 total protein stain (LiCOR) was used
for loading control (Figure 12).
The results of JAG1, Notch1 and Notch3 profiling with western blot are presented in
figure 13. Although JAG1 and Notch1 expression levels seem to vary somewhat in
different strains of BON1 cells (figure 13) on the image shown here, quantification of
several repeats revealed no differences in Notch1, Notch3 and JAG1 levels (figure 14).
Expression levels of Notch2, Notch4 and DLL1 were not investigated due to the lack of
functional antibodies.

Figure 12: Total protein stain. Membranes A, B and C were used for detection of JAG1, Notch1 and
Notch3, respectively. Each well was loaded with 10 µg of protein. The membranes were stained with
Revert 700 total protein stain to verify the balanced sample loading.

34

Figure 13: JAG1, Notch1 and Notch3 expression in BON1 cells. Expression levels were investigated
in BON WT, SSTR5 OE and two SSTR5 KO (clones A11 & C8) cells. The two SSTR5 KO clones were
used to verify that the detected effect is SSTR5 KO-specific.

Figure 14: Quantification of (A) Notch1, (B) Notch3 and (C) JAG1 protein levels. Levels of the target
proteins were normalised to the total protein signal (REVERT stain). The protein levels of Notch1,
Notch3 and JAG1 did not differ in BON WT, SSTR5 OE and SSTR5 KO cells. Standard error of the
mean is shown; the number of the individual repeats (n) for A, B and C are 4, 2 and 3.

35

4.2 SSTR2 and SSTR5 expression does not affect proliferation of BON1
cells in vitro
Cell counting was used in order to study whether varying levels of SSTRs could affect
proliferation of BON1 cells. Cell counting was done by plating 0.5 million BON1 WT,
SSTR5 OE, SSTR2/5 KO, SSTR2 KO and two types of SSTR5 KO cells and counting
them after 24 h and 48 h. After 24 h the number of cells had doubled to approximately 1
million cells and after 48 h there was a six-fold increase in cell numbers. There were no
significant differences in proliferation between the cell types after 24 h or 48 h (Figure
15).

Figure 15: Proliferation of BON1 cells after 24 h (blue) and 48 h (red). Proliferation rate was studied
by plating 500 000 cells in a 25 cm2 plate and counting the cells after 24 h and 48 h. A two-fold increase
can be observed after 24 h and a six-fold increase after 48 h. However, SSTR2 and 5 expression did not
have any significant effect on BON1 proliferation rate. Standard error of the mean is shown, n=5.

WST8 assay was used to supplement these findings, since the absorption from WST8
dye is proportional to the number of viable cells. Differences in the WST8 assay could
also be coupled to metabolic changes, since WST8-related discoloration reflects cellular
respiration (reduction of NAD+). When the cells were grown in regular medium with
10% FBS, BON1 WT, SSTR5 OE, SSTR2 KO and SSTR2/5 KO had similar
proliferation rate, whereas BON1 SSTR5 KO cells showed a significant increase in
absorption levels (figure 16). When the cells were cultured in starvation medium, there
was a profound decrease in absorption compared to cells grown in regular medium, but
no difference across the cell types could be observed.

36

Figure 16: WST8 assay with BON1 cells in regular medium (blue) and starvation medium (pink).
Regular medium contained 10% FBS, whereas starvation medium had 0.2% FBS. No significance in cell
viability was demonstrated between BON1 WT, SSTR5 OE, SSTR2 KO and SSTR2/5 KO, whereas the
viability was significantly increased in BON1 SSTR5 KO cells. There were no differences when BON1
cells were cultured in starvation medium. Absorbance was read at 450 nm. One-way ANOVA with
Dunnett’s multiple comparisons test, n=3.

4.3 BON1 SSTR5 KO cells show enhanced Notch response to JAG1
stimulation
In a co-culture experiment performed by the intern Jemiine Ahlgren (supplemental
image 1) BON1 cells were used as Notch signal sending cells and HEK FLN1 cells
were used as Notch signal receiving cells. BON1 WT was the only subtype of BON1
cells, which showed a trend towards increased Notch induction in HEK FLN1 after 6 h,
though the differences were not statistically significant. After 24 h, all the strains of
BON1 cells induced similar rate of Notch signalling in HEK FLN1 cells.
I compared different strains of BON1 cells in terms of their response to Notch ligands,
for which I undertook the above described co-culture assay in the reverse design, i.e. I
used BON1 cells for signal receiving cells (figure 17). For this purpose BON1 cells
were transfected with 12xCSL-Fluc and SV40-hRluc, and then co-cultured with the
signal inducing cells, 3T3 JAG1. HEK FLN1-cells were co-cultured with 3T3 JAG1
cells as a positive control. Notch activity in BON1 and HEK FLN1 cells was measured
with the Dual-Glo luciferase assay (described in section 3.4.2). BON1 WT, SSTR5 OE,

37

SSTR2 KO and SSTR2/5 KO cells showed similar Notch response to JAG1, but BON1
SSTR5 KO cells demonstrated significantly increased CSL activity.

Figure 17: Co-culture assay for Notch induction: BON1 cells as signal receiving cells. BON1 cells,
which were transfected with the reporter gene 12xCSL-Fluc were used as Notch signal receiving cells and
co-cultured with the 3T3 JAG1 as signal sending cells. HEK FLN1 cells were used as a positive control.
BON1 SSTR5 KO cells showed enhanced Notch response to JAG1 as compared to BON1 WT, SSTR5
OE, SSTR2 KO and SSTR2/5 KO cells. One-way ANOVA with Dunnett’s multiple comparisons test,
n=4.

To verify whether the same findings could be reproduced with a different method, the
Notch activity was induced by JAG1 peptides instead of 3T3 JAG1 cells. For this
purpose, BON1 WT, SSTR5 KO and SSTR5 OE cells were plated on 0.1 µg/ml, 0.5
µg/ml, 2 µg/ml and 5 µg/ml JAG1 peptides. HEK FLN1 cells were used as a positive
control. Same concentrations of IgG Fc were used for background control. Wells
without JAG1 or IgG coating were used as a second background control.
When 12xCSL-Fluc and SV40-hRluc-transfected BON1 cells were cultured on JAG1
peptides, Notch signalling increased along with the concentration of peptides (figure
18). After 2 µg/ml the Notch signalling did not increase in BON1 WT and SSTR5 KO.
In HEK FLN1 cells, Notch signalling did not change between 0.5 and 2 µg/ml, but at 5
µg/ml more CSL activity was observed. When Notch signalling was activated with
peptides, there was no difference in Notch activity in BON1 WT and SSTR5 KO cells.
BON1 SSTR5 OE cells showed less Notch signalling than BON1 WT and SSTR5 KO.

38

Figure 18: Activation of Notch signalling with JAG1 peptides. In order to induce Notch signalling in
BON1 cells, the cells were transfected with the reporter gene 12xCSL-Fluc and seeded onto JAG1
peptide-precoated plates. IgG Fc was used as a background control. BON1 WT and SSTR5 KO showed
no differences, whereas BON1 SSTR5 OE demonstrated less of Notch induction. One-way ANOVA with
Dunnett’s multiple comparisons test, n=2.

39

5 Discussion
5.1 SSTR levels does not affect expression of Notch receptors and JAG1 in
BON1 cells
Notch signalling is important in the differentiation and development of the pancreatic
endocrine cells. Thus, Notch signalling could also have a role in the progression of
PNETs. PNETs overexpress SSTRs and previous studies have hinted to a connection
between SSTR5 and JAG1. In order to understand, whether different SSTR2 and
SSTR5 levels could affect expression of Notch receptors 1, -3 and the Notch ligand
JAG1 in BON1 cells, I carried out a set of western blot experiments. Although no
differences in Notch receptors and JAG1 protein levels were detected in BON1 cells
with varying SSTR2 and -5 levels (figure 13 and 14), there could still be functional
differences, since Notch signalling is regulated by PTMs, which could affect for
example the degradation of the NICD. Another possibly important aspect here is the
localisation of Notch receptors and ligands in different intracellular compartments,
which is challenging to study with western blot. In order to study levels of Notch
receptors and ligands in the plasma membrane and other cellular compartments,
immunofluorescence could be used as a supplementary approach. It would also be
interesting to study whether there are differences in DLL1 expression in BON1 cells
with different SSTR expression, since Notch pathway could be inhibited by DLL1
through HES1/ASCL1 signalling in PNETs (Johansson et al., 2009; Mohammed et al.,
2011). However, a DLL1 antibody, which I tried to validate in OP9 GFP and OP9
DLL1 OE cells failed to show specificity (data not shown) and thus another more
reliable antibody would be required to address this question. The dynamics of levels of
Notch receptors and ligands during and after SSTR activation could also be worthy
investigating.

5.2 Expression levels of SSTR2 and SSTR5 do not affect proliferation in
BON1 cells in vitro
SSTR2 and SSTR5 are known to regulate cell proliferation through the MAPK
pathway, NOS signalling and PI3K pathway and thus could affect the baseline
proliferation rate in BON1 cells (Theodoropoulou & Stalla, 2013). Activation of Notch
signalling in BON1 cells has been shown to inhibit cell cycle and thus differences in
proliferation could also be coupled to Notch activity (Nakakura et al., 2005). Possible
40

differences in proliferation rate of BON1 cells with different SSTR2 and SSTR5
expression could be coupled to differences in the baseline activity of these receptors or,
perhaps, to Notch activity. To study in vitro proliferation of BON1 cells in respect to
SSTR levels, the same number of cells of different types were plated, allowed to grow
and counted after 24 and 48 h. We found no differences in proliferation across all the
cell types studied in vitro (figure 15). However, the cells with different SSTR
expression levels still had different proliferation rates in vivo (figure 9A), which could
be possibly linked to endogenous SST stimulation or, perhaps, to effects from other
signalling pathways that crosstalk with SSTRs.
WST8 assay was used in combination with cell counting since the absorbance of the
WST8 dye is proportional to dehydrogenase activity and thus reflects the number of
viable cells (figure 16). When BON1 cells were cultured in the regular medium there
was no difference in the absorbance from BON1 WT, SSTR5 OE and SSTR2/5 KO
cells. In BON1 SSTR5 KO cells a significant increase in the WST8 absorbance was
observed. Thus, an increase in the absorbance would be expected also in the SSTR2/5
KO cells, however, this was not the case. Since cell counting did not show differences
in proliferation, the increase in WST8 absorbance in SSTR2 KO and SSTR5 KO cells
could result from increased metabolical activity of the above strains. Glycolysis assay or
oxygen consumption assay could for example be used to study if these cells have
increased metabolical activity.
In addition to the above, cells could be stained for the proliferation marker Ki-67 or
MCM-2. Cells could also be cultured with nucleoside analogues, bromodeoxyuridine
and ethynyldeoxyuridine, which are incorporated to the DNA during proliferation and
can be further detected with appropriate techniques. Apoptosis could be studied with
caspase activity assays or by western blot against apoptotic markers such as Bax,
caspase-8 or p53 (Ward et al., 2008).

41

5.3 BON1 cells obtain altered responsiveness to JAG1 stimulation with loss
of SSTR5
The levels of Notch receptors and JAG1 do not directly reflect the activity of Notch
pathway. Thus, to study the functionality of the pathway, I used a co-culture assay,
where 12xCSL-Fluc-transfected BON1 cells served as Notch signal-receiving cells and
3T3 JAG1 cells served as signal-sending cells (figure 17). With this approach, we found
that Notch transcriptional activity in response to JAG1 in the BON1 SSTR5 KO was
increased as compared to BON1 WT, SSTR5 OE, SSTR2 KO and SSTR2/5 KO cells.
This evidence supports the connection between SSTR5 and Notch signalling. SSTR5
has an activating effect on the PLC pathway, and is known to inhibit MAPK pathway,
Ca2+ channels, NOS signalling and adenylyl cyclase (Theodoropoulou & Stalla, 2013).
Since we have found no differences in Notch receptor and JAG1 expression levels, we
speculate that Notch signalling in BON1 SSTR5 KO could be differently modulated by
the above-mentioned pathways. This line of thinking is supported by earlier evidence,
demonstrating importance of the same pathways for regulation of Notch signalling. The
Notch target gene repressor Groucho and Drosophila Suppressor of hairless (Su(H),
commonly CSL) have shown to be phosphorylated by MAPK (Hasson & Paroush,
2006; Nagel et al., 2017). Intracellular Ca2+ levels, which are regulated by Ca2+ channels
and the PLC pathway, have been shown to affect the transcription of Notch target genes
by activating calcium/calmodulin-dependent protein kinase IV (CAM kinase) which, in
turn, up-regulated transcriptional activity of CSL in neuronal cells (Mckenzie et al.,
2005). Nitric oxide can affect the nuclear localisation of NICD and thus, the
transcriptional activity of CSL could also be affected (Bosse et al., 2013). The cAMP
pathway has also been shown to modulate Notch activation, possibly by regulating γsecretase activity, since CREB is important for the assembly of γ-secretase (AnguloRojo et al., 2013).
In order to verify these results, we repeated the experiment with a different approach by
inducing Notch signalling in BON1 cells with JAG1 peptides (figure 18). When Notch
signalling was activated in BON1 cells with JAG1 peptides, adsorbed on culture plates,
the results did not match the earlier data obtained in co-culture studies with the same
cells. Namely, the transcriptional response in BON1 WT and SSTR5 KO cells was the
same and exceeded the response in the SSTR5 OE cells. These data are intriguing and
presently we do not have a clear explanation for that. An increase in Notch activity
42

could be observed in control cells (HEK FLN1) along with the increase in ligand
concentration, which indicates that the assay was functionally valid. However, the assay
might have suffered from several technical issues that could have affected the results.
One of this is non-physiologic ligand presentation in the approach with the culture plate.
In the co-culture setup, ligands are sitting in the plasma membranes of viable cells and
are presented to signal receiving cells as such, and thus this condition is more
physiological. In the assay with plate-immobilised ligands, on the contrary, the JAG1
peptides are attached to cell culture plates and the number of ligands and their
directionality is unknown. Also, in the assay with the plate-immobilised JAG1, although
the wells were washed carefully with a multichannel pipette during the coating, there
might have been some loss of the JAG1 peptides during the washing steps. This could
be further investigated by coating wells with the different peptide concentrations and
then running a protein staining (for example, Coomassie) to ensure that the coating is
even.
Besides, Notch signal did not increase in BON1 WT and SSTR5 KO cells after 2 µg/ml
of JAG1. Presently, we do not know whether Notch activation reached saturation
already at 2 μg/ml, so it would be important to investigate Notch responsiveness to
higher levels of ligands, beyond 5 µg/ml.
Since the co-culture assay and the assay with the immobilised JAG1 peptides gave
different results, the functionality of both methods should be carefully verified. In the
co-culture setup, it would be important to know if the signal-receiving and -sending
cells are evenly distributed in the wells and what is the density of cell-to-cell contacts. It
would also be important to validate JAG1 levels in the 3T3 cells, since overexpression
of JAG1 by these cells could have been lost or gone down over time.

43

6 Conclusions
Notch signalling could possibly become a drug target in PNETs, yet the pathway and its
regulation in these tumours are still not well understood. Previous studies demonstrated
that transcriptional upregulation of Notch1 in PNETs was therapeutically promising.
My in vitro experiments show that BON1 cells with different SSTR2 and SSTR5
expression have the same levels of Notch1, Notch3 and JAG1. However, despite this,
BON1 cells with loss of SSTR5 do act differently in in vivo models of PNET
xenotransplantation and, which is more important, are selectively responsive to
treatment with JAG1 antibody. This evidence hints that the observed differences are
likely to be mediated by something else, for example altered regulation of Notch
pathway in SSTR5 KO cells, and not the absolute number of Notch receptors and
ligands. This concept is supported by my results with the co-coculture experiment,
where CSL showed increased transcriptional activity in the SSTR5 KO cells. However,
when Notch signalling was activated by plate-immobilised JAG1 peptides, BON WT
and SSTR5 KO cells had similar Notch response, which exceeded the one of BON1
SSTR5 OE cells. Thus, two different assays produced conflicting results. There might
be several explanations for this discrepancy and the functionality of the two methods
needs to be further validated in order to estimate the reliability of the evidence.
In the future, stability and degradation rates of the NICD could be studied in SSTR5 KO
and SSTR 5OE cells. It would be also important to reveal, which Notch receptor is
specifically regulated by SSTR5. Subsequent studies of JAG1-signalling in PNETS are
also needed. Indeed, JAG1 inhibition could also affect other interactions than JAG1Notch. Earlier, ADAM17, ADAM10 and BACE1 cleavage sites have been described in
JAG1 and JAG1 cleavage has been shown to promote migration and induce EMT
markers in colorectal cancer (He et al., 2014; Pelullo et al., 2019)

44

7 Acknowledgements
My MSc project was done in the Cell Fate lab in Åbo Akademi University and I would
like to thank Cecilia Sahlgren and the whole group for having me as a master student. I
also want to thank Valeriy and Veronika for being my main supervisors. Without
Veronika I would probably never have started this project and me, as well as the rest of
the group miss you very much. Although the work was stressful at times, I have had a
really fun time in the group, both in the lab and during the activities outside the lab. I
have also learned many new techniques during my master’s, and I feel like my skills in
lab work and in scientific way of thinking have improved during these two years. I
would also want to thank Jemiine Ahlgren and Ignacio Pardo, who were doing
internships in the group and helped with some experiments for a few months. Finally, I
would also like to thank all my friends and family for the support.

45

8 References
Adler J. T., Hottinger D. G., Kunnimalaiyaan M. & Chen H. (2008) “Histone deacetylase
inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells”, Surgery, Vol.
144, No. 6, Pages 956-961, doi: 10.1016/j.surg.2008.08.027
Angulo-Rojo C., Manning-Cela R., Aguirre A., Ortega A. & López-Bayghen E. (2013)
“Involvement of the Notch pathway in terminal astrocytic differentiation: role of PKA”, ASN
Neuro, Vol. 5, No. 5, e00130, doi: 10.1042/AN20130023
Arruga F., Vaisitti T. & Deaglio S. (2018) “The NOTCH pathway and its mutations in mature B
cell malignancies”, Frontiers in Oncology, Vol. 8, Article: 550, doi: 10.3389/fonc.2018.00550
Baudin E., Gigliotti A., Ducreux M., Ropers J., Comoy E., Sabourin J. C., Bidart J. M., Cailleux
A. F., Bonacci R., Ruffié P. & Schlumberger M. (1998) “Neuron-specific enolase and
chromogranin A as markers of neuroendocrine tumours”, British journal of cancer, Vol. 78, No.
8, Pages 1102-1107
Bigas A., Martin D. K. & Milner L. A. (1998) “Notch1 and Notch2 inhibit myeloid
differentiation in response to different cytokines”, Molecular and Cellular Biology, vol. 18, No.
4, Pages 2324-2333, doi: 10.1128/mcb.18.4.2324
Boareto M., Jolly M. K., Lu M., Onuchic J. N., Clementi C. & Ben-Jacob E. (2015) “JaggedDelta asymmetry in Notch signaling can give rise to a sender/receiver hybrid phenotype”,
PNAS, Vol. 112, No. 3, Pages 402-409, doi: 10.1073/pnas.1416287112
Bodei L., Sundin A., Kidd M., Prasad V. & Modlin I. M. (2015) “The Status of Neuroendocrine
Tumor Imaging: From Darkness to Light?”, Neuroendocrinology, Vol. 101, No. 1, Pages 1-17,
doi: 10.1159/000367850
Bosse K., Hans C. P., Zhao N., Koenig S. N., Huang N., Auggilam A., LaHaye S., Tao G.,
Lucchesi P. A., Lincoln J., Lilly B. & Gard V. (2013) “Endothelial nitric oxide signaling
regulates Notch1 in aortic valve disease”, Journal of Molecular and Cellular Cardiology, Vol.
60, Pages 27-35, doi: 10.1016/j.yjmcc.2013.04.001
Cabrera O., Berman D. M., Kenyon N. S., Ricordi C., Berggren P. O. & Caicedo A. (2006)
“The unique cytoarchitecture of human pancreatic islets has implications for islet cell function”,
PNAS, Vol. 103, No. 7, Pages 2334-2339, doi: 10.1073/pnas.0510790103
Chamchoy K., Pakotiprapha D., Pumirat P., Leartsakulpanich U. & Boonyuen U. (2019)
“Application of WST-8 based colorimetric NAD(P)H detection for quantitative dehydrogenase
assays”, BMC Biochemistry, Vol. 20, No. 4, Pages 1-14, doi: 10.1186/s12858-019-0108-1

46

Chauhan A., Farooqui Z., Murray L. A., Weiss H. L., Myint Z. W., Raajasekar A. K. A., Evers
B. M., Arnold S. & Anthony L. (2018) “Capecitabine and Temozolomide in Neuroendocrine
Tumor of Unknown Primary”, Journal of Oncology, Vol. 2018, Article ID 3519247, Pages 1-6,
doi: 10.1155/2018/3519247
Conkright M. D., Guzmán E., Flechner L., Su A. I., Hogenesch J. B. & Montminy M. (2003)
“Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP
responsiveness”, Molecular Cell, Vol. 11, No. 4, Pages 1101-1108, doi: 10.1016/S10972765(03)00134-5
Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., Shih T. & Yao J. C. (2017) “Trends
in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors
in the United States”, JAMA oncology, Vol. 3, No. 10, Pages 1335-1342, doi:
10.1001/jamaoncol.2017.0589
Dasgupta P. (2004) “Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia,
and angiogenesis”, Pharmacology & Therapeutics, Vol. 102, No. 1, Pages 61-85, doi:
10.1016/j.pharmthera.2004.02.002
Fahnestock S. R., Alexander P., Nagle J. & Filpula D. (1986) “Gene for an ImmunoglobulinBinding Protein from a Group G Streptococcus”, Journal of Bacteriology, Vol. 167, No. 3,
Pages 870-880, doi: 10.1128/jb.167.3.870-880.1986
Florio T., Thellung S., Arena S., Corsaro A., Bajetto A., Schettini G. & Stork P. K. (2000)
“Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the
activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2”,
Journal of Physiology-Paris, Vol. 94, No. 3-4, Pages 239-250, doi: 10.1016/S09284257(00)00214-X
Foltz D. R., Santiago M. C., Berechid B. E. & Nye J. S. (2002) “Glycogen synthase kinase-3β
modulates Notch signaling and stability”, Current Biology, Vol. 12, No. 12, Pages 1006-1011,
doi: 10.1016/S0960-9822(02)00888-6
Fraenkel M., Kim M., Faggiano A., de Herder W. W., Valk G. D. & Knowledge NETwork
(2014) “Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the
literature”, Endocrine-Related Cancer, Vol. 21, No. 3, Pages R153-R163, doi: 10.1530/ERC13-0125
Franko-Tobin L. G., Mackey L. V., Huang W., Song X., Jin B., Luo J., Morris L. M., Liu M.,
Fryer C. J., White J. B. & Jones K. A. (2012), “Notch1-mediated tumor suppression in cervical
cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted

47

therapeutics”,

Molecular

Cell,

Vol.

16,

No.

4,

Pages

509-520,

doi:

10.1016/j.molcel.2004.10.014
Fryer C. J., Lamar E., Turbachova I., Kintner C. & Jones K. A. (2002) “Mastermind mediates
chromatin-specific transcription and turnover of the Notch enhancer complex”, Genes &
Development, Vol. 16, No. 11, Pages 1397-1411, doi: 10.1101/gad.991602
Fuseiler J. A., Coy D. H., Wu L. & Sun L. (2012) “Notch1-Mediated Tumor Suppression in
Cervical Cancer with the Involvement of SST Signaling and Its Application in Enhanced SSTRTargeted

Therapeutics”,

the

Oncologist,

Vol.

17,

Nr.

2,

Pages

220-232,

doi:

10.1634/theoncologist.2011-0269
Golson M. L., Lay J. L., Gao., N., Brämswig N., Loomes K. M., Oakey R., May C. L., White P.
& Kaestner K. H. (2009) “Jagged1 is a competitive inhibitor of Notch signalling in the
embryonic pancreas”, Mechanisms of Development, Vol. 126, No. 8-9, Pages 687-699, doi:
10.1016/j.mod.2009.05.005
Gomez-Lamarca M. J., Falo-Sanjuan J., Stojnic R., Rehman S. A., Muresan L., Jones M. L.,
Cerda-Moya G., Yuan Z., Balou S., Valenti P., Bystricky K., Payre F., O’Holleran K., Kovall R.
& Bray S. J. (2018) “Activation of the Notch signalling pathway in vivo ellicts changes in CSL
nuclear

dynamics”,

Developmental

cell,

Vol.

44,

No.

5,

Pages

611-623,

doi:

10.1016/j.devcel.2018.01.020
Hai L., Zhang C., Li T., Zhou X., Liu B., Li S., Zhu M., Lin Y., Yu S., Zhang K., Ren B., Ming
H., Huang Y., Chen L., Zhao P., Zhou H., Jiang T. & Yang X. (2018) “Notch1 is a prognostic
factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that
promotes glioma cell survival via the NF-κB(p65) pathway”, Cell Death and Disease, Vol. 9,
No. 2, Page 158, doi: 10.1038/s41419-017-0119-z
Harvey B.M., Rana N. A., Moss H., Leonardi J., Jafar-Nejad H. & Haltiwanger R. S. (2016)
“Mapping sites of O-glycolysation and fringe elongation on Drosophila Notch”, Journal of
Biological Chemistry, Vol. 291, No. 31, Pages 16348-16360, doi: 10.1074/jbc.M116.732537
Hasson P. & Paroush Z. (2006) “Crosstalk between the EGFR and other signalling pathways at
the level of the global transcriptional corepressor Groucho/TLE”, British Journal of Cancer,
Vol. 94, No. 6, Pages 771-775, doi: 10.1038/sj.bjc.6603019
Hauso O., Gustafsson B. I., Kidd M., Waldum H. L., Drozdov I., Chan A. K. C. & Modlin I. M.
(2008) “Neuroendocrine tumor epidemiology: contrasting Norway and North America”,
Cancer, Vol. 113, No. 10, Pages 2655-2664, doi: 10.1002/cncr.23883

48

Haynes C. M., Sangoi A. R. & Pai R. K. (2011) “PAX8 is expressed in pancreatic welldifferentiated

neuroendocrine

tumors

and

in

extrapancreatic

poorly

differentiated

neuroendocrine carcinomas in fine-needle aspiration biopsy specimens”, Cancer cytopathology,
Vol. 119, No. 3, Pages 193-201, doi: 10.1002/cncy.20136
He W., Hu J., Xia Y. & Yan R. (2014) “β-Site Amyloid Precursor Protein Cleaving Enzyme
1(BACE1) Regulates Notch Signaling by Controlling the Cleavage of Jagged 1 (Jag1) and
Jagged 2 (Jag2) Proteins”, The Journal of Biological Chemistry, Vol. 289, No. 30, Pages 2063020637, doi: 10.1074/jbc.M114.579862
Hein K., Mittler G., Cizelsky W., Kühl M., Ferrante F., Liefke R., Berger I. M., Just S., Sträng
J. E., Kestler H. A., Oswald F. & Borggrefe T. (2015) ”Site-specific methylation of Notch1
controls the amplitude and duration of the Notch response”, Science Signaling, Vol. 8, No. 369,
ra30, doi: 10.1126/scisignal.2005892
Ikeuchi T. & Sisodia S. S. (2003) “The Notch Ligands, Delta1 and Jagged2, Are Substrates for
Presenilin-dependent “γ-Secretase” Cleavage”, The journal of Biological chemistry, Vol. 278,
No. 10, Pages: 7751-7754, doi: 10.1074/jbc.C200711200
Jiao Y., Shi C., Edil B. H., de Wilde R. F., Klimstra D. S., Maitra A., Schulick R. D., Tang L.
H., Wolfgang C. L., Choti M. A., Velculescu V. E., Diaz Jr. L. A., Vogelstein B., Kinzler K.
W., Hruban R. H. & Papadopoulos N. (2011) “DAXX/ATRX, MEN1 and mTOR pathway
genes are frequently altered in pancreatic neuroendocrine tumours”, Science, Vol. 331, No.
6021, Pages 1199-1203, doi: 10.1126/science.1200609
Johansson T. A., Westin G. & Skogseid B. (2009) “Identification of Achaete-scute complex-like
1 (ASCL1) target genes and evaluation of DKK1 and TPH1 expression in pancreatic endocrine
tumours”, BMC Cancer, Vol. 9, No. 321, doi: 10.1186/1471-2407-9-321
Kelgiorgi D. & Dervenis C. (2017) “Pancreatic neuroendocrine tumours: the basics, the gray
zone, and the target”, F1000 Research, Version 1, doi: 10.12688/f1000research.10188.1
Keutgen X. M., Nilubol N. (2016) “Surgical resection of primary tumor site is associated with
prolonged survival in metastatic non-functioning pancreatic neuroendocrine tumors”, Surgery,
Vol. 159, No. 1, Pages 311-319, doi: 10.1016/j.surg.2015.05.042
Kishore G., Veerankutty F. H., Ramesh N. & Basil Culas T. (2016) “Median pancreatectomy
done in a rural median college – A case report”, Indian Journal of Surgical Oncology, Vol. 7,
No. 1, Pages 79-81, doi: 10.1007/s13193-015-0439-3

49

Kleeff J., Diener M. K., Z’graggen K., Hinz U., Wagner M., Bachmann J., Zehetner J., Müller
M. W., Friess H. & Büchler M. W. (2007) “Distal pancreatectomy”, Annals of Surgery, Vol.
245, No. 4, Pages 573-582, doi: 10.1097/01.sla.0000251438.43135.fb
Kovall R. A., Gebelein B., Sprinzak D. & Kopan R. (2017) “The canonical Notch signalling
pathway: Structural and Biochemical insights into shape, sugar and force”, Developmental cell,
Vol 41, No. 3, Pages 228-241, doi: 10.1016/j.devcel.2017.04.001
LaFoya B., Munroe J. A. & Albig A. R. (2019) “A comparison of resveratrol and other
polyphenolic compounds on Notch activation and endothelial cell activity”, PLOS ONE, Vol.
14, No. 1, e0210607, doi: 10.1371/journal.pone.0210607
Lammert E., Brown J. & Melton D. A. (2000) “Notch gene expression during pancreatic
organogenesis”, Mechanisms of Development, Vol. 94, No. 1-2, Pages 199-203, doi:
10.1016/S0925-4773(00)00317-8
Langridge P. D. & Struhl G. (2017) “Epsin-dependent ligand endocytosis activates Notch by
force”, Cell, Vol. 171, No. 6, Pages 1383-1396, doi: 10.1016/j.cell.2017.10.048
Li X., Cai L., Xu H., Geng C., Lu J., Tao L., Sun D., Ghishan F. K. & Wang C. (2016)
“Somatostatin regulates NHE8 protein expression via the ERK1/2 MAPK pathway in DSSinduced colitis mice”, American Journal of Physiology, Vol. 311, No. 5, Pages 954-963, doi:
10.1152/ajpgi.00239.2016
Liew C. W., Vockel M., Glassmeier G., Brandner J. M., Fernandez-Ballester G. J., Schwarz J.
R., Schulz S., Buck F., Serrano L., Richter D. & Kreienkamp H-J. (2008) “Interaction of the
human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables
somatostatin to control permeability of epithelial tight junctions”, FEBS Letters, Vol. 583, No.
1, Pages 49-54, doi: 10.1016/j.febslet.2008.11.048
Liu M., Springstead Scanlon C., Banerjee R., Russo N., Inglehart R. C., Willis A. L., Weiss S. J.
& D’Silva N. J. (2013) “The histone methyltransferase EZH2 mediates tumour progression on
the chick chorioallantoic membrane assay, a novel model of head and neck squamous cell
carcinoma”, Translational Oncology, Vol. 6, No. 3, Pages 273-281
Logeat F., Bessia C., Brou C., LeBail O., Jarriault S., Seidah N. G. & Israël A. (1998) “The
Notch1 receptor is cleaved constitutively by a furin-like convertase”, PNAS, Vol. 95, No. 14,
Pages 8108-8112, doi: 10.1073/pnas.95.14.8108
Ludvigsen E., Stridsberg M., Taylor J. E., Culler M. D., Öberg K. & Janson E. T. (2004)
“Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and

50

sst5

in

BON-1

cells”,

Madical

oncology,

Vol.

21,

No.

3,

Pages

285-295,

doi: 10.1385/MO:21:3:285
Luo G., Javed A., Strosberg J. R., Jin K., Zhang Y., Liu C., Xu J., Soares K., Weiss M. J.,
Zheng L., Wolfgang C. L., Cives M., Wong J., Wang W., Sun J., Shao C., Wang W., Tan H., Li
J., Ni Q., Shen L., Chen M., He J., Chen J. & Yu X. (2017) “Modified staging classification for
pancreatic neuroendocrine tumours on the basis of the american joint committee on cancer and
european neuroendocrine tumor society systems”, Journal of clinical oncology, Vol. 35, No. 3,
Pages 274-282, doi: 10.1200/JCO.2016.67.8193
MacGoran D., Münch J. & de la Pompa J. L. (2018) “Notch and interacting signalling pathways
in cardiac development, disease and regeneration”, Nature Reviews, Vol. 15, No. 11, Pages 685704, doi: 10.1038/s41569-018-0100-2
Marotta V., Nuzzo V., Ferrara T., Zuccoli A., Masone M., Nocerino L., Del Prete M., Marciello
F., Ramundo V., Lombardi G., Vitale M., Colao A. & Faggiano A. (2012) “Limitations of
Chromogranin A in clinical practice”, Biomarkers, Vol. 17, No. 2, Pages 186-191, doi:
10.3109/1354750X.2012.654511
Mckenzie G. J., Stevenson P., Ward G., Papadia S., Bading H., Chawla S., Privalsky M. &
Hardingham G. E. (2005) “Nuclear Ca2+ and CaM kinase IV specify hormonal- and Notchresponsiveness”, Journal of Neurochemistry, Vol. 93, No. 1, Pages 171-185, doi:
10.1111/j.1471-4159.2005.03010.x
Mehta S., de Reuver P. R., Gill P., Andrici J., D’Urso L., Mittal A., Pavlakis N., Clarke S.,
Samra J. S. & Gill A. J. (2015) ”Somatostatin receptor SSTR-2a expression is a stronger
predictor for survival than Ki-67 in pancreatic neuroendocrine tumors”, Medicine, Vol. 94, No.
40, e1281, doi: 10.1097/MD.0000000000001281
Meuten D. J., Moore F. M. & George J. W. (2016) “Mitotic Count and the Field of View Area:
Time to Standardize”,

Veterinary Pathology, Vol.

53,

No.

1, Pages

7-9,

doi:

10.1177/0300985815593349
Missiaglia E., Dalai I., Barbi S., Baghelli S., Falconi M., della Peruta M., Piemonti L., Capurso
G., Di Florio A., delle Fave G., Pederzoli P., Croce C. M. & Scarpa A. (2010) “Pancreatic
Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway”, Journal
of clinical oncology, Vol. 28, No. 8, Pages 245-255, doi: 10.1200/JCO.2008.21.5988
Modlin I. M., Drozdov I. & Kidd M. (2013) “The Identification of Gut Neuroendocrine Tumor
Disease by Multiple Synchronous Transcript Analysis in Blood”, PLOS One, Vol. 8, No. 5,
e63364, doi: 10.1371/journal.pone.0063364

51

Mohammed T. A., Holen K. D., Jaskula-Sztul R., Mulkerin D., Lubner S. J., Schelman W. R.,
Eickhoff J., Chen H. & LoConte N. K. (2011) “A pilot phase II study of valproic acid for
treatment of low-grade neuroendocrine carcinoma”, The Oncologist, Vol. 16, No. 6, Pages 835843, doi: 10.1634/theoncologist.2011-0031
Morgan T. H. (1917) “The theory of gene”, The American naturalist, Vol. 51, Pages 513-544
Mumm J. S., Schroeter E. H., Saxena M T., Griesemer A., Tian X., Pan D. J., Ray W. J. &
Kopan R. (2000) “A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic
activation of Notch1”, Molecular cell, Vol. 5, No. 2, Pages 197-206, doi:
Murtaugh L. C., Stanger B. Z., Kwan K. M. & Melton D. A. (2003) “Notch signalling controls
multiple steps of pancreatic differentiation”, PNAS, Vol. 100, No. 25, Pages 14920-14925, doi:
10.1073/pnas.2436557100
Nagel A. C., Auer J. S., Schulz A., Pfannstiel J., Yuan Z., Collins C. E., Kovall R. A. & Preiss
A. (2017) “Phosphorylation of Suppressor of Hairless impedes its DNA-binding activity”,
Scientific Reports, Vol. 7, No.1, Article: 11820, Pages doi: 10.1038/s41598-017-11952-0
Nakakura E. K., Sriuranpong V. R., Kunnimalaiyaan M., Hsiao E. C., Schuebel K. E., Borges
M. W., Jin N., Collins B. J., Nelkin B. D., Chen H., Ball D. W. (2005) “Regulation of
neuroendocrine differentiation in gastrointestinal carcinoid tumour cells by Notch signaling”,
the Journal of Clinical Endocrinology & Metabolism, Vol. 90, No. 7, Pages 4350-4356, doi:
10.1210/jc.2005-0540
Nandagopal N., Santat L. A., LeBon L., Sprinzak D., Bronner M. E. & Elowitz M. B. (2018)
“Dynamic ligand discrimination in the Notch signalling pathway”, Cell, Vol. 172, No. 4, Pages
869-880, doi: 10.1016/j.cell.2018.01.002
Nandagopal N., Santat L. A. & Elowitz M. B. (2019) “Cis-activation in the Notch signaling
pathway”, eLife, Vol. 8, e37880, doi: 10.7554/eLife.37880
Okajima T., Xu A. & Irvine K. D. (2003) “Modulation of Notch-ligand binding by protein Ofucosyltransferase 1 and Fringe” The Journal of Biological Chemistry, Vol. 278, No. 43, Pages
42340-42345, doi: 10.1074/jbc.M308687200
Palomero T., Lim W. K., Odom D. T., Sulis M. L., Real P. J., Margolin A., Barnes K. C.,
O’Neil J., Neuberg D., Weng A. P., Aster J. C., Sigaux F., Soulier J., Look A. T., Young R. A.,
Califano A. & Ferrando A. A. (2006) “NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth”, PNAS, Vol. 103, No.
48, Paged 18261-18266, doi: 10.1073/pnas.0606108103

52

Panzuto F., Severi C., Cannizzaro R., Falconi M., Angeletti S., Pasquali A., Corleto V. D.,
Annibale B., Buonadonna A., Pederzoli P. & Fave G. D. (2004) “Utility of combined use of
plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal
and pancreatic endocrine tumours”, Journal of Endocrinological Investigation, Vol. 27, No. 1,
Pages 6-11, doi: 10.1007/BF03350903
Parks L. & Routt M. (2015) “Total pancreatectomy with islet cell transplation for the treatment
of pancreatic cancer”, Clinical Journal of Oncology Nursing, Vol. 19, No. 4, Pages 479-481,
doi: 10.1188/15.CJON.479-481
Pelullo M., Nardozza F., Zema S., Quaranta R., Nicoletti C., Besharat Z. M., Felli M. P.,
Cerbelli B., d’Amati G., Palermo R., Capalbo C., Talora C., Di Marcotullio L., Giannini G.,
Checquolo S., Screpanti I. & Bellavia D. (2019) “Kras/ADAM17-dependent Jag1-ICD reverse
signalling sustains colorectal cancer progression 3 and chemoresistance”, Cancer Research,
Vol. 79, No. 21, Pages 5575-5586, doi: 10.1158/0008-5472.CAN-19-0145
Penton A. L., Leonard L. D. & Spinner N. B. (2012) “Notch signaling in human development
and disease”, Seminars in Cell and Developmental Biology, Vol. 23, No. 4, Pages 450-457, doi:
10.1016/j.semcdb.2012.01.010
Pedraza-Arévalo S., Hormaechea-Agulla D., Gómez-Gómez E., Requena M. J., Selth L. A.,
Gahete M. D., Castaño J. P. & Luque R. M. (2017) “Somatostatin receptor subtype 1 as a
potential diagnostic marker and therapeutic target in prostate cancer”, The Prostate, Vol. 77,
No. 15, Pages 1499-1511, doi: 10.1002/pros.23426
Pintar A., De Biasio A., Popovic M., Ivanova N. & Pongor S. (2007) “The intracellular region
of Notch ligands: does the tail make the difference?”, Biology direct, Vol. 2, No. 19, doi:
10.1186/1745-6150-2-19
Pirot P., van Grunsven L. A., Marine J-C., Huylebroeck D. & Bellefroid E. J. (2004) “Direct
regulation of the Nrarp gene promoter by the Notch signaling pathway”, Biochemical and
Biophysical

Research

Communications,

Vol.

322,

No.

2,

Pages

526-534,

doi:

10.1016/j.bbrc.2004.07.157
Popko-Scibor A. E., Lindberg M. J., Hansson M. L., Holmlund T. & Wallberg A. E. (2011)
“Ubiquitination of Notch1 is regulated by MAML1-mediated p300 acetylation of Notch1”,
Biochemical and Biophysical Research Communications, Vol. 416, No. 3-4, Pages 300-306,
doi: 10.1016/j.bbrc.2011.11.030
Proweller A., Tu L., Lepore J. J., Cheng L., Lu M. M., Seykora J., Millar S. E., Pear W. S. &
Parmacek M. S. (2006) “Impaired Notch signaling promotes de novo squamous cell carcinoma

53

formation”, Cancer research, Vol. 66, No. 15, Pages 7438-7444, doi: 10.1158/0008-5472.CAN06-0793
Qian Z., Li T., Ter-Minassian M., Yang J., Chan J., Brais L., Masugi Y., Thiaglingam A.,
Brooks N., Nishihara R., Bonnemarie M., Masuda A., Inamura K., Kim S., Mima K., Sukawa
Y., Dou R., Lin X., Christiani D., Schmidlin F., Fuchs C., Mahmood U., Ogino S. & Kulke M.
(2017) “Association Between Somatostatin Receptor Expression and Clinical Outcomes in
Neuroendocrine

Tumors”,

Pancreas,

Vol.

45,

No.

10,

Pages

1386-1393,

doi:

10.1097/MPA.0000000000000700
Ramirez R. A., Beye D. T., Chauhan A., Boudreaux J. P., Wang Y-Z. & Woltering E. A. (2016)
“The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors” Oncologist,
Vol. 21, No. 6, Pages 671-675, doi: 10.1634/theoncologist.2015-0470
Raymond E., Dahan L., Raoul J-L., Bang Y-J., Borbath I., Lombard-Bohas C., Valle J.,
Metrakos P., Smith D., Vinik A., Chen J-S., Hörsch D., Hammel P., Wiedenmann B.,Van
Cutsem E., Patyna S., Lu D. R., Blanckmeister C., Chao R. and Ruszniewski P. (2011)
“Sunitinib malate for the treatment of pancreatic neuroendocrine tumours”, The new England
journal of medicine, Vol. 364, No. 6, Pages 501-513, doi: 10.1056/NEJMoa1003825
Rocheville M., Lange D. C., Kumar U., Sasi R., Patel R. C. & Patel Y. C. (2000) “Subtypes of
the somatostatin receptor assemble as functional homo- and heterodimers”, The journal of
biological chemistry, Vol. 275, no. 11, Pages 7862-7869, doi: 10.1074/jbc.275.11.7862
Sallinen V., Haglund C. & Seppänen H. (2015) “Outcomes of resected nonfunctional pancreatic
neuroendocrine tumours: Do size and symptoms matter?”, Surgery, Vol. 158, No. 6, Pages
1556-1563, doi: 10.1016/j.surg.2015.04.035
Sampedro-Núñez M., Luque R. M., Ramos-Levi A. M., Gahete M. D., Serrano-Somavilla A.,
Villa-Osaba A., Adrados M., Ibáñez-Costa A., Martín-Pérez E., Culler M. D., Marazuela M. &
Castaño J. P. (2016) “Presence of sst5TMD4, a truncated splice variant of the somatostatin
receptor subtype 5, is associated to features of increased aggressiveness in pancreatic
neuroendocrine

tumors”,

Oncotarget,

Vol.

7,

No.

6,

Pages

6593-6608,

doi:

10.18632/oncotarget.6565
Schmid H. A., Lambertini C., van Vugt H. H., Barzaghi-Rinaudo P., Schäfer J., Hillenbrand R.,
Sailer A. W., Kaufmann M. & Nuciforo P. (2012) “Monoclonal antibodies against the human
somatostatin receptor subtypes 1-5: development and immunohistochemical application in
neuroendocrine tumors”, Neuroendocrinology, Vol. 95, No. 3, Pages 232-247, doi:
10.1159/000330616

54

Sharma K., Patel Y. C. & Srikant C. B. (1996) “Subtype-selective induction of wild-type p53
and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3”, Molecular
Endocrinology, Vol. 10, No. 12, Pages 1688-1696, doi: 10.1210/mend.10.12.8961277
Scholzen T. & Gerdes J (2000) “The Ki-67 Protein: From the Known and the Unknown”,
Journal of Cellular Physiology, Vol. 182, No. 3, Pages 311-322, doi: 10.1002/(SICI)10974652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
Singh N. K., Kotla S., Kumar R. & Rao G. N. (2015) “Cyclic AMP response element binding
protein mediates pathological retinal neovascularization via modulating DLL-NOTCH1
signaling”, EBioMedicine, Vol. 2, No. 11, Pages 1767-1784, doi: 10.1016/j.ebiom.2015.09.042
Six E., Ndiaye D., Laâbi Y., Brou C., Gupta-Rossi N., Israël A. & Logeat F. (2003) “The Notch
ligand Delta1 is sequentially cleaved by an ADAM protease and γ-secretase”, PNAS, Vol. 100,
No. 13, Pages 7638-7643, doi: 10.1073/pnas.1230693100
Sjöqvist M., Antfolk D., Ferraris S., Rraklli V., Haga C., Antila C., Mutvei A., Imanishi S. Y.,
Holmberg J., Jin S., Eriksson J. E., Lendahl U., Sahlgren C. (2014) “PKCζ regulates Notch
receptor routing and activity in a Notch signalling-dependent manner”, Nature, Vol.

24, No. 4, Pages 433-450, doi: 10.1038/cr.2014.34
Smith A. T., Santama N., Dacey S., Edwards M., Bray R. C., Thorneley R. N. F. & Burke J. F.
(1990) “Expression of a synthetic gene for horseradish peroxidase C in Escherichia coli and
folding and activation of the recombinant enzyme with Ca2+ and heme”, The Journal of
Biological Chemistry, Vol. 265, No. 22, Pages 13335-13343

Steentoft C., Vakhrushev S. Y., Joshi H. J., Kong Y., Vester-Christensen M. B.,
Schjoldager K. T-B. G., Lavrsen K., Dabelsteen S., Pedersen N. B., Marcos-Silva L.,
Gupta R., Bennet E. P., Mandel U., Brunak S., Wandall H. H., Levery S. B. & Clausen H.
(2013) “Precision mapping of the human O‐GalNAc glycoproteome through SimpleCell
technology”, EMBO, Vol. 32, No. 10, Pages 1478-1488, doi: 10.1038/emboj.2013.79
Stroh T., Jackson A. C., Dal Farra C., Schonbrunn A., Vincent J. P. & Beaudet A. (2000)
“Receptor-Mediated Internalization of Somatostatin in Rat Cortical and Hippocampal Neurons”,
Synapse, Vol. 38, No. 2, Pages 177-186, doi: 10.1002/1098-2396(200011)38:2<177::AIDSYN9>3.0.CO;2-S
Sun L., Qian Q., Sun G., Mackey L. V., Fuselier J. A., Coy D. H. & Yu C-Y. (2015) “Valproic
acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted
peptide-drug conjugated via activating somatostatin receptor type II”, Journal of Drug
Targeting, Vol. 42, No. 2, Pages 169-177, doi: 10.3109/1061186X.2015.1066794

55

Takeuchi H., Yu H., Hao H., Takeuchi M., Ito A., Li H. & Haltiwanger R. S. (2017) “OGlycosylation modulates the stability of epidermal growth factor-like repeats and thereby
regulates Notch trafficking”, Journal of Biological Chemistry, Vol. 292, No. 38, Pages 1596415973, doi: 10.1074/jbc.M117.800102
Thangaraju M., Sharna K., Leber B., Andrews D. W., Shen S-H. & Srikant C. B. (1999)
“Regulation of acidification and apoptosis by SHP-1 and Bcl-2”, The Journal of Biological
Chemistry, Vol. 274, No. 41, Pages 29549-29557, doi: 10.1074/jbc.274.41.29549
Theodoropoulou M. & Stalla G. K. (2013) “Somatostatin receptors: from signalling to clinical
practice”, Frontiers in Neuroendocrinology, Vol. 34, No. 3, Pages 228-252, doi:
10.1016/j.yfrne.2013.07.005
Tian G., Sandler S., Gylfe E. & Tengholm A., 2011, “Glucose- and hormone-induced cAMP
oscillations in α- and β-cells within intact pancreatic islets”, Diabetes, Vol. 60, No. 5, Pages
1535-1543, doi: 10.2337/db10-1087
Trofimiuk-Müldner M. & Hubalewska-Dydejczyk A., 2015, “Somatostatin: The history of
discovery”, Somatostatin Analogues: From Research to Clinical Practice, 1st edition
Tsai S. Q., Zheng Z., Nguyen N. T., Liebers M., Topkar V. V., Thapar V., Wyvekens N.,
Khayter C., Iafrate A. J., Le L. P., Aryee M. J. & Joung J. K. (2015) “GUIDE-seq enables
genome-wide profiling of off-target

cleavage

by CRISPR-Cas

nucleases”,

Nature

Biotechnology, Vol. 33, No. 2, Pages 187-197, doi: 10.1038/nbt.3117
Vaccari T., Lu H., Kanwar R., Fortini M. E. & Bilder D. (2008) “Endosomal entry regulates
Notch receptor activation in Drosophila melanogaster”, journal of Cell Biology, Vol. 180, No.
4, Pages 755-762, doi: 10.1083/jcb.200708127
Vandamme T., Beyens M., de Beeck K. O., Dogan F., van Koetsveld P. M., Pauwels P., Mortier
G., Vangestel C., de Herder W., Van Camp G., Peeters M. & Hofland L. J. (2016) “Long-term
acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with
novel PI3K-AKT-mTOR inhibitors”, British journal of cancer, Vol. 114, No. 6, Pages 650-658,
doi: 10.1038/bjc.2016.25
Van de Walle I., Waegemans E., De Medts J., De Smet G., De Smedt M., Snauwaert S.,
Vandekerckhove B., Kerre T., Leclercq G., Plum J., Gridley T., Wang T., Koch U., Radtke R. &
Taghon T. (2013) ”Specific Notch reporter-ligand interactions control human TCR-αβ/γδ
development by inducing differential Notch signal strength”, The Journal of Experimental
Medicine, Vol. 210, No. 4, Pages 683-697, doi: 10.1084/jem.20121798

56

Wang H., Chen Y., Fernandez-Del Castillo C., Ylimaz O. & Deshpande V. (2013)
“Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a
critical look at notch signaling pathway”, Nature Modern Pathology, Vol. 26, No. 1, Pages 139147, doi: 10.1038/modpathol.2012.143
Ward T. H., Cummings J., Dean E., Greystoke A., Hou J. M., Backen A., Ranson M. & Dive C.
(2008) “Biomarkers of apoptosis”, British Journal of Cancer, Vol. 99, No. 6, Pages 841-846,
doi: 10.1038/sj.bjc.6604519
Weng A. P., Ferrando A. A., Lee W., Morris IV J. P., Silverman L. B., Sanchez-Irizarry C.,
Blacklow S. C., Look A. T. & Aster J. C. (2004) “Activating mutations of NOTCH1 in human T
cell acute lymphoblastic leukemia”, Science, Vol. 306, No. 5694, Pages 269-271, doi:
10.1126/science.1102160
de Wilde R. F., Edil B. H., Hruban R. H. & Maitra A. (2012) “Well-differentiated pancreatic
neuroendocrine tumours: from genetics to therapy”, Nature rewiews Gastroenterology &
hepatology, Vol 9, No. 4, Pages 199-208, doi: 10.1038/nrgastro.2012.9
Wyche T. P., Dammalapati A., Cho H., Harrison A. D., Kwon G. S., Chen H., Bugni T. S. &
Jaskula-Sztul R. (2014) “Thiocoraline activates the Notch pathway in carcinoids and reduces
tumour progression in vivo”, Cancer gene therapy, Vol. 21, No. 12, Pages 518-525, doi:
10.1038/cgt.2014.57
Yang X., Klein R., Tian X., Cheng H-T., Kopan R. & Shen J. (2004) “Notch activation induces
apoptosis in neural progenitor cells through a p53-dependent pathway”, Developmental Biology,
Vol. 269, No. 1, Pages 81-94, doi: 10.1016/j.ydbio.2004.01.014
Yao J. C., Pavel M., Phan A. T., Kulke M. H., Hoosen S., St Peter J., Cherfi A. & Öberg K. E.
(2011) “Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with
Advanced pNET Treated with Everolimus”, The Journal of Clinical Endocrinology &
Metabolism, Vol. 96, No. 12, Pages 3741-3749, doi: 10.1210/jc.2011-0666
Zheng X., Linke S., Dias J. M., Zheng X., Gradin K., Wallis T. P., Hamilton B. R., Gustafsson
M., Ruas J. L., Wilkins S., Bilton R. L., Brismar K., Whitelaw M. L., Pereira T., Gorman J. J.,
Ericson J., Peet D. J., Lendahl U. & Poellinger L. (2008) “Interaction with factor inhibiting
HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling
pathways”, PNAS, Vol. 105, No. 9, Pages 3368-3373, doi: 10.1073/pnas.0711591105
Zitzer H., Richter D. & Kreienkamp H-J. (1999a) “Agonist-dependent interaction of the rat
somatostatin receptor subtype 2 with cortactin-binding protein 1”, Journal of biological
chemistry, Vol. 274, No. 26, Pages 18153-18156, doi: 10.1074/jbc.274.26.18153

57

Zitzer H., Hönk H-H., Bächner D., Richter D. & Kreienkamp H-J. (1999b) “Somatostatin
receptor interacting protein defines a novel family of multidomain proteins present in

human and rodent brain”, Journal of biological chemistry, Vol. 274, No. 46, Pages 3299733001, doi: 10.1074/jbc.274.46.32997
Ämmälä C., Ashcroft F. M. & Rorsman P. (1993) “Calcium-indipendent potentiation of insulin
release by cyclic AMP in single β-cells”, Nature, Vol. 363, No. 6427, Pages 356-358,
doi: 10.1038/363356a0

58

9 Supplementary figures

Supplementary figure 1: The co-culture assay for Notch induction: BON1 as signal-sending cells.
BON1 cells were used as signal sending cells and were co-cultured with HEK FLN1, transfected with
12xCSL-Fluc luciferase reporter gene. The cells were co-cultured for 6 h (blue) and 24 h (red). HEK
FLN1 cells were also co-cultured with 3T3 JAG1 cells (positive control) and mCardinal transfected HEK
cells (background control). One-way ANOVA with Dunnett’s multiple comparisons test, n=3.

59

10 Recipes and buffers
Washing buffer (2 l)

5% Blocking buffer (50 ml)

200 ml 10x PBS

3 g fat-free milk powder

1800 ml MQ-H2O

50 ml PBS + 0.3% Tween

6 ml Tween-20

10x Running buffer (4 l)

0.2 M Stripping buffer (500 ml)

120 g Tris-Base

7.5 g glycine

576 g Glycine

500 ml MQ-H2O

Add MQ-H2O up to 4 l

Adjust pH to 2.0

Add 5 ml 20% SDS

1x Transfer buffer (1 l)

3x Laemmli buffer (100 ml)

200 ml 5x transfer buffer

30 ml 100% glycerol

200 ml 100% methanol

15 ml 20% SDS

600 ml MQ-H2O

30 ml 0.625 M Tris-HCl pH 6.8

5x Semi-dry transfer buffer (2 l)

10 ml 0.15% bromphenol blue

72.75 g Tris-Base

12 ml MQ-H2O

36.63 g glycine

Add 300 µl β-mercaptoethanol to 9.7 ml
3x Laemmli before use

Add MQ-H2O up to 2 l

8% acrylamide gel (4 gels)

1x Running buffer (1 l)

6 ml lower gel stock

100 ml 10x running buffer

0.12 ml 20% SDS

900 ml MQ-H2O

6.4 ml Acrylamide

5 ml 20% SDS

11.6 ml MQ-H2O

Add 5 ml 20% SDS to 1 l buffer before
use

0.12 ml 10% APS
0.012 ml TEMED
60

10% acrylamide gels (4 gels)

Lower gel stock (500 ml)

6 ml lower gel stock

90.75 g Tris-Base

0.12 ml 20% SDS

500 ml MQ-H2O

8 ml Acrylamide

Adjust pH to 8.8

10 ml MQ-H2O

Upper gel stock (500 ml)

0.12 ml 10% APS

30.26 g Tris-Base

0.012 ml TEMED

500 ml MQ-H2O

Upper gel (4 gels)

Adjust pH to 6.8

2.5 ml Upper gelstock (pH 6.8)

Enhanced chemiluminescence

0.05 ml 20% SDS

1.5 ml SuperSignal West Pico PLUS
Luminol/Enhancer solution

1.5 ml Acrylamide

1.5 ml SuperSignal West Pico PLUS

6 ml MQ-H2O

Stable Peroxide Solution

0.04 ml 10% APS

XXXXXX

0.02 ml TEMED

60

11 Svensk sammanfattning
11.1 Introduktion
Bukspottkörtelns neuroendokrina tumörer (PNET, eng. pancreatic neuroendocrine
tumour) är sällsynta tumörer som uppstår från bukspottskörtelns hormonutsöndrande
celler i de Langerhanska öarna och bukspottskörtelgångarna. PNET:er utgör 7 ̶ 9 % av
alla neuroendokrina tumörer i matsmältningssystemet och bukspottskörteln (GEP-NET,
eng. gastroenteropancreatic NET). PNET:er uppstår oftast sporadiskt men i 10 % av
fallen är de associerade med genetiska sjukdomar så som multipel endokrin neoplasi typ
1 (MEN1) och von Hippel-Lindau-syndrom (VHL). PNET:erna kan delas in i
väldifferentierade tumörer och tumörer med låg differentieringsgrad. Väldifferentierade
PNET:erna kan vidare kategoriseras i hormonutsöndrande och icke-hormonutsöndrande
tumörer varav de icke-hormonutsöndrande är vanligare. De hormonutsöndrande
tumörerna utsöndrar höga hormonhalter som kan orsaka hormonspecifika symptom hos
patienten. Vilken typ av hormon som utsöndras beror på ursprungscellen, till exempel
tumörer från β-cellerna producerar och utsöndrar insulin. De icke-hormonutsöndrande
tumörerna utsöndrar också sekretionsvesikler men producerar låga mängder av
hormoner, vilket kan orsaka ospecifika symptom (Kelgiorgi & Dervenis, 2017; Wilde,
2012). De vanligaste genmutationerna som förekommer hos PNET:erna är MEN1 (44,1
%) som är viktig för cellcykelreglering och DAXX/ATRX (42,6 %) som påverkar
insättning av histon 3.3 till telomerer. Dessutom kan signalräckan fosfatidylinositol 3kinas (PI3K eng. phosphoinositide 3-kinase) påverkas av mutationer hos PTEN (7,3 %)
och TSC1/2 (8,8 %). Normalt är PTEN och TSC1/2 viktiga för inhiberingen av PI3Ksignalering (Jiao et al., 2011).
I USA förekom PNET:er hos 6,98 per 100 000 personer år 2012 och fallen har ökat 6,4
gånger från år 1973 enligt databasen SEER18 (eng. Surveillance, Epidemiology, and
End Results 18) (Dasari et al., 2017). Förhöjd detektion av PNET:er kan vara en följd av
ökad användning visualiserings- och detektionstekniker av matsmältningsorganen.
Dessa tekniker innebär till exempel magnetisk resonanstomografi (MRI, eng. magnetic
resonance imaging) och positronemissionstomografi (PET) (Bodei et al., 2015).
Dessutom har avbildningsteknikerna förbättrats och tumörer detekteras då de inte ännu
har bildat metastaser. Ytterligare till användning av medicinsk visualisering, har
tumörmarkörer, till exempel Chromogranin A (CgA) och neuronspecifik enolas (NSE)
använts för diagnos (Yao et al., 2011). För att uppskatta tumörstadiet används WHO
61

2010 graderingssystem där mängden av prolifererande celler kan detekteras genom Ki67-färgning (figur 1). Dessutom används graderingssystem från European NET society
(ENETS) och American committee of cancer (AJCC) som också inkluderar
metastasering i graderingen (figur 2; Luo et al., 2017). Tumörstadiet och
metastaseringen påverkar överlevnaden hos patienterna. Patienterna med metastas
överlever i medeltal 12 månader medan patienterna med lokaliserade tumörer har en
förväntad överlevnad på 30 år (Dasari et al., 2017). Det mest effektiva sättet att
avlägsna PNET:er är operation (Keutgen et al., 2016). I samband med operationen kan
tumörspridningen hindras med everolimus som inhiberar PI3K-signalräckan samt
sunitinib som inhiberar receptortyrosinkinaser (Vandamme et al., 2016; Raymond et al.,
2011). Octreotide och lanreotide är läkemedel som används för att sänka
hormonutsöndringen genom att aktivera somatostatin receptorer (SSTR), efter som
SSTR:er är överuttryckta i PNET:erna (Theodoropoulou & Stalla, 2013).
SSTR:erna aktiveras av somatostatin (SST; figur 4) och aktiveringen av SSTR:erna
leder till inhibering av hormonutsöndring och proliferation i dessa tumörer (figur 5;
Theodoropoulou & Stalla, 2013). SSTR:erna är G-proteinkopplade receptorer (GPCR,
eng. G protein-coupled receptor) och fem SSTR:er, SSTR1 ̶ 5, har beskrivits hos
däggdjur. Aktiveringen av de fem receptorerna har en inhiberande effekt på adenylyl
cyclas vars aktivering leder till produktion av cyklisk adenosinmonofosfat (cAMP).
cAMP kan aktivera proteinkinas A (PKA) som fosforylerar målproteiner, så som
transkriptionsfaktorn cAMP-responselement bindande protein (CREB). cAMP har
också visats främja utsöndringen av hormoner. Dessutom påverkar de fem SSTR:erna
flera andra signalerings räckor genom att aktivera eller inhibera dem. Till dessa hör K+och Ca2+-kanaler vars aktivering också påverkar utsöndring av utsöndringsgranuler,
mitogenaktiverat proteinkinas (MAPK) och PI3K som reglerar proliferation,
apoptossignalräckor, och fosfolipas C (PLC, eng. phospholipase C) vars aktivering
frigör Ca2+ från det endoplasmatiska nätverket (ER, eng. endoplasmic reticulum)
(Theodoropoulou & Stalla, 2013). Signaleringen genom SSTR:erna kan regleras genom
protein-proteinväxelverkan och SSTR2 har visats binda till andra proteiner, till exempel
cortactin-bindande protein 1 (CortBP1), via en PDZ-domän. (Zitzer et al., 1999a).
SSTR-aktiveringen kan leda till receptorendocytos, vilket minskar mängden av
receptorer vid plasmamembranen samt receptoraktiveringen. Endocytos påverkas av
receptor- samt celltyp och det har visats att SSTR2, SSTR3 och SSTR5 endocyteras
62

mest effektivt (Stroh et al., 2000). Aktiveringen av SSTR:erna har visats bilda
receptorspecifika dimerer. I en studie där SSTR5 aktiverades med SST-14, bildade
SSTR5 dimerer med SSTR1 och dimererna endocyterades. Detta kunde inte detekteras
hos celler som uttryckte SSTR5 och SSTR4 (Rocheville et al., 2000).
Notch-signaleringsräckan är en evolutionärt välbevarad cell-cell signaleringsräcka där
Notch-receptorer hos signalmottagande celler kan aktiveras av Notch-ligander hos
signalsändande celler (figur 6). Därtill kan receptorerna och liganderna på samma cell
växelverka tillsammans i en process som kallas cis-inhibering eller -aktivering (Boareto
et al., 2015; Nandagopal et al., 2019). Hos däggdjur finns det fyra transmembrana
Notch-receptorer, Notch1 ̶ 4. Notch-receptorerna aktiveras av de fem transmembrana
liganderna Jagged1 (JAG1), JAG2, Delta-lik1 (DLL1), DLL3 och DLL4 (Hai et al.,
2018). Notch-receptor aktiveringen sker då ligandernas och receptorernas extracellulära
epidermala tillväxtfaktor-domäner (EGF, eng. epidermal growth factor) interagerar med
varandra (figur 7). För att aktivera Notch-signaleringen, endocyteras liganden hos den
signalsändande cellen. Detta skapar en dragningskraft mellan Notch-receptorn och
liganden vilket öppnar en negativt reglerande domän (NRR, eng. negative regulatory
region) och presenterar ett klyvnings ställe hos Notch-receptorns extracellulära domän
(Langridge & Struhl, 2017). Klyvnings stället känns igen av enzymet disintegrin och
metalloproteas (ADAM, eng. a disintegrin and metalloprotease) som klyver Notch. Den
transmembrana domänen av NECD samt NICD förblir kvar vid plasmamembranet och
kallas för Notch extracellulär avkortning (NEXT, eng. Notch extracellular truncation).
NEXT känns igen och klyvs av det transmembrana proteinkomplexet γ-sekretas vilket
frigör NICD:en till kärnan (Mumm et al., 2000; Kovall et al., 2017). I kärnan binder
NICD:en till transkriptionsfaktorn CSL (CBF1/RBPJ, Su(H) och Lag-1) vilket leder till
rekrytering av ko-aktiverare och transkription av Notch-målgenerna HEY och HES
(Wyche et al., 2014; Gomez-Lamarca et al., 2018). Notch-signaleringen kan regleras
genom posttranslationella modifieringar (PTM) och till dem hör fosforylering,
ubikvitinering, acetylering och metylering av NICD medan NECD kan modifieras av Oglucosylering (figur 8). PTM:ar i NECD:en kan påverka receptor-ligand interaktioner
medan PTM:ar i NICD:en påverkar till exempel Notch-receptor endocytos, samt
nedbrytningen av NICD:en (Fryer et al., 2004; Popko-Scibor et al., 2011; Sjöqvist et
al., 2014; Hein et al., 2015; Takeuchi et al., 2017).

63

11.2 Hypotes och målsättning
PNET:erna är sällsynta tumörer och det finns endast lite information om deras
molekylära signalerings mekanismer (Kelgiorgi & Dervenis, 2017). Kirurgiska ingrepp
är det enda sättet att avlägsna tumörerna. Farmaceutiska ingrepp används för att
minimera tumörprogressionen och för att lindra symptom från hormonöversekretionen
(Theodoropoulou & Stalla, 2013). Låg Notch-signalering har observerats i dessa
tumörer och aktivering av Notch-signaleringen har visat minska proliferation och
uttryck av tumörmarkörerna chromogranin A (CgA) samt neuronspecifik enolas (NSE)
hos tumörerna (Nakakura et al., 2005; Mohammed et al., 2011). För att aktivera Notchsignaleringen i dessa tumörer har histon deacetylas inhibitorer använts för att öka
transkriptionen av Notch1 (Adler et al., 2008). Tidigare i C. Sahlgrens labb har BON1celler transplanterats i möss med nedsatt immunitet. BON1-celler vars SSTR2- och
SSTR5-uttryck var avlägsnad (SSTR2/5 KO, eng. knock out) producerade större
tumörer jämfört med BON1-celler med endogen SSTR-uttryck (WT, eng. wild type) och
SSTR5-överuttryckande (OE, eng. overexpressing) BON1-celler (figur 9A). Hos BON1
SSTR2/5 KO-cellerna observerades också högre JAG1-uttryck, medan BON1 SSTR5
OE-cellerna visade låg JAG1-uttryck (figur 9B). I ett annat in vivo experiment
transplanterades BON1 WT- och SSTR5 KO-celler i möss med nedsatt immunitet och
mössen behandlades med en antikropp mot JAG1. BON1 SSTR5 KO-cellerna
producerade större tumörer än BON WT-cellerna och dessutom detekterades en
minskning i tumörstorlek då JAG1 inhiberades hos BON1 SSTR5 KO-tumörerna (figur
10). Då mössen behandlades med en JAG1-inhiberande antikropp, minskade
tumörstorleken endast hos BON1 SSTR5 KO-tumörerna. Detta tyder på samspel mellan
SSTR:erna och Notch-signaleringen, möjligtvis genom JAG1 och hypotesen i denna
avhandling är att det finns en koppling mellan Notch-signaleringen och SSTR:erna.

64

11.3 Material och metoder
11.3.1 Celler
För att studera hur Notch-signaleringen växelverkar med SSTR:erna användes BON1celler som härstammar från en PNET som metastaserats till lymfknutarna. BON1cellerna som användes i experimenten var BON1 med endogen SSTR-uttryck (BON
WT), BON1-celler med avlägsen SSTR2- och SSTR5-expression (SSTR2 KO och
SSTR5 KO), BON1 som överuttrycker SSTR5 (SSTR5 OE), samt kombinerad SSTR2och SSTR5 KO (SSTR2/5 KO). BON1-cellerna odlades i ett 1:1 förhållande av DMEM
(Sigma) och F12K Nut mix (Gibco). Cellodlings mediet var kompletterat med 10 %
fetalt kalvserum (FBS, eng. fetal bovine serum), 100 U/ml penicillin och 100 µg/ml
streptomycin. Dessutom användes HEK 293-celler (eng. human embryonic kidney cells)
som uttrycker den fullständiga Notch1-receptorn (FLN1) och mus fibroblast cellinjen
3T3 som överuttrycker JAG1. HEK FLN1-cellerna odlades i DMEM med 10 % fetalt
kalvserum, 2 Mm L-Glutamin, 100 U/ml penicillin och 100 µg/ml streptomycin. 3T3
JAG1-cellerna odlades i DMEM med 10 % fetalt kalvserum, 2 Mm L-Glutamin, och 0,5
µg/ml puromycin. Cellerna inkuberades i 37°C med 5 % CO2.

11.3.2 WST8
NAD+ är en koenzym som reduceras till NADH i mitokondrier vid respiration då syre är
tillgängligt. I närvaro av NADH, reduceras WST8-reagens till ett orange vattenlösligt
färgämne som sprids till cellkulturmediet (figur 11). Färgintensiteten från den
reducerade WST8-reagensen kan sedan användas för att mäta proliferation hos celler.
För att studera hur BON1-celler prolifererar vid olika ämnesomsättnings tillstånd
odlades BON1-cellerna i en 96-håls platta med 100 µl cellodlingsmedium med 10 %
FBS eller 0,2 % FBS (näringsfattig). Efter 46 h tillsattes 10 µl WST8-reagens i
brunnarna för en slutlig koncentration av 10 %. Plattorna inkuberades 2 h i 37 °C,
varefter absorbansen mättes med mikroplattläsaren Hidex vid 450 nm.

65

11.3.3 Western blot
För att mäta proteinmängden i BON1-celler, upplöstes cellernas lipider, proteiner och
DNA till en heterogen blandning med 3x Laemmli buffert som innehöll 3 % βmercaptoetanol. Proteinkoncentrationen mättes med Pierce 660-analys där proteinerna
binder till ett komplex som består av en metall och ett färgämne. Då proteinet binder till
komplexet, skiftas färgämnets maximala absorbans som mäts vid 660 nm. Absorbansen
hos proven mättes med Hidex och analyserades i Excel (Microsoft) med hjälp av en
BSA-standardkurva vars koncentrationer var redan kända.
För att analysera mängden målprotein, användes SDS-PAGE där proteiner från
cellysaten separeras enligt deras storlek i en polyakrylamidgel. Gelen består av en övre
gel som samlar alla proteiner i en front och en nedre gel som separerar proteinerna. De
större proteinerna migrerar långsammare och lokaliseras till gelens övre del medan de
mindre proteinerna migrerar snabbare och således längre i gelen. Gelerna sattes i en
tank som fylldes med 1x körbuffert. För att ta bort positiva laddningar hos proteinerna,
tillsattes 20 % SDS i bufferten. I gelens brunnar pipetterades 10–12 µg protein och i en
brunn pipetterades 5 µl av protein markören Precision Plus Protein Dual Color Standard
(Bio-Rad) som användes för att verifiera målproteinets storlek. Proven separerades med
120 V i 1,5 h. Proteinerna flyttades sedan från gelen till en nitrocellulosamembran (GE
healthcare, Amersham) med porstorleken 0,45 µm. För detta sattes en björntunga, två
Whatmann-papper, polyakrylamidgelen, nitrocellulosa membranen, två Whatmann
papper och en björntunga ihop i en kassett. Kassetten placerades i en transfertank med
1x transferbuffert. Proteinerna överfördes från gelen till membranen genom att föra in
100 V i 1 h till transfersystemet. Efter att cellerna flyttats till membranen sköljdes
membranen med MQ H2O. För att se om transfern fungerat och att varje brunn har lika
mycket protein, färgades alla proteinerna på membranen med REVERT-proteinfärg (LiCOR) i 5 min. Färgen visualiserades med ChemiDoc MP (Biorad) vid 700 nm.
Proteinfärgen tvättades bort med en buffert som tar bort REVERT-proteinfärgen (LiCOR). Membranen tvättades med tvättbuffert och sedan blockerades membranen med 5
% mjölkpulver i PBS i 1 h. Membranen tvättades åter med tvättbuffert och sedan
inkuberades membranen över natten i 4 °C med en primär antikropp som binder till
målproteinet. Nästa dag tvättades membranen med tvättbuffert. Membranen inkuberades
med en sekundär antikropp som känner till och binder till den primära antikroppen. Den
sekundära antikroppen är också kopplad till enzymet pepparrots peroxidas (HRP, eng.
66

horseradish peroxidase) som producerar ljus då HRP utsätts för ECL-reagens (eng.
enhanced chemiluminescence). Ljuset visualiserades med ChemiDoc imaging system
(Biorad).

11.3.4 Experiment med rapportörgen
Rapportörgen är en gen vars genuttryck kan mätas då målproteinet inducerar
transkription av målgenerna. Transkriptionsaktiviteten mäts genom att transfektera
celler med en plasmid som har en promotorregion dit transkriptionsregleraren som
studeras binder till, och en rapportörgen som kodar för ett fluorescerande protein eller
luciferas. Då det transkriptionsreglerande proteinet binder till promotorregionen
induceras transkriptionen av rapportörgenen. Signalen från rapportörgenen kan sedan
mätas och är jämförbar med transkriptionen av genen som studeras. I detta projekt
användes en plasmid med 12xCSL som promotorregion och lysmaskluciferas (Fluc, eng.
Firefly luciferase) som rapportörgen. Dessutom användes plasmiden SV40-hRluc som
innehåller en luciferasgen från korallarten Renilla reniformis (Rluc, eng. Renilla
luciferase). SV40-hRluc användes som en kontroll för transfektionseffektivitet eftersom
Renilla-luciferasgenen uttrycktes kontinuerligt. För att mäta transkriptionen av Notchmålgener aktiverades lysmaskluciferaset med kommersiell lysmaskluciferin (Dual-Glo,
Promega) varefter det producerade ljuset mättes med mikroplattläsaren EnSight (Perkin
Elmer). I plattan tillsattes sedan Stop & Glo-reagens (Perkin Elmer) som innehöll
Renilla-luciferassubstratet Renilla-luciferin, samt lysmaskluciferasinhibitor och ljuset
från Renilla luciferin mättes med EnSight.

11.4 Resultat
11.4.1 Profilering av Notch-receptorer och JAG1 hos BON1-celler
Westernblot användes för att studera uttrycket av JAG1 och Notch-receptorerna i BON1
WT-, SSTR5 KO- och SSTR5 OE-celler. Två SSTR5 KO-kloner användes för att
verifiera att effekten som observeras är specifik då BON1-celler inte uttrycker SSTR5.
De båda klonerna (klon A11 och C8) saknade SSTR5-uttryck men hade olika
mutationer. Antikropparnas funktion bekräftades före analysen. Som laddningskontroll
användes proteinfärgning av den totala proteinmängden. Inga skillnader hos JAG1-,
Notch1- och Notch3-uttryck detekterades hos BON WT-, SSTR5 OE- och SSTR5 KOcellerna (figur 13 och 14). Notch2-, Notch4- och DLL1-nivåer kunde inte undersökas på
grund av brist av fungerande antikroppar.
67

11.4.2 Proliferation hos BON1-celler med olika SSTR2- och SSTR5uttryck
Proliferationen hos BON1-celler med olika SSTR2- och SSTR5-nivåer studerades
genom att odla 500 000 celler i 24 h och 48 h varefter cellerna räknades. Efter 24 h hade
cellerna fördubblats och efter 48 h hade cellmängden ökat sexdubblats (figur 15). Inga
proliferationsskillnader mellan cellerna kunde identifieras. Dessutom användes WST8analys eftersom absorbansen från denna analys är jämförbar med mängden levande
celler (figur 16). BON1 WT-, SSTR5 OE-, SSTR2 KO- och SSTR2/5 KO-cellerna
visade inga proliferationsskillnader då de odlades i ett medium med 10 % FBS, medan
absorbansen från BON1 SSTR5 KO-cellerna visade en signifikant ökning. Då cellerna
odlades i näringsfattigt medium med 0,2 % FBS var absorbansen från WST8-reagensen
lägre än då cellerna odlades i 10 % FBS, men inga absorbans skillnader mellan cellerna
detekterades.

11.4.3 BON1 som Notch-signalmottagande celler
I ett tidigare samkultur experiment av J. Ahlgren, som var praktikant vid C. Sahlgrens
forskningsgrupp, hade BON1-celler med olika SSTR2- och SSTR5-uttryck inte visat
skillnader som Notch-signalsändande celler (tillägsfigur 1). För att studera om SSTR2
och SSTR5-uttrycket kunde påverka Notch-aktiviteten då BON1-cellerna är Notchsignalmottagande celler, transfekterades BON1-cellerna med 12xCSL-Fluc samt hRlucSV40 och sedan odlades cellerna i samkultur med 3T3 JAG1-celler, som var Notchsignalsändande celler (figur 17). En samkultur där HEK FLN1-celler odlades med 3T3
JAG1-celler användes som en positiv kontroll. 24 h efter transfektionen mättes luciferas
aktiviteten i BON1-cellerna och ljuset från luciferaset är jämförbar med CSLaktiviteten. CSL-aktiviteten hos BON1 WT-, SSTR5 OE-, SSTR2 KO- och SSTR2/5
KO-cellerna var lika medan hos BON1 SSTR5 KO-cellerna observerades en signifikant
ökning i CSL-aktiviteten.
För att verifiera resultaten från samkultur experimentet där BON1-cellerna användes
som signalmottagande celler, användes plattor täckta med JAG1-peptid för att aktivera
Notch hos BON1 WT-, SSTR5 KO- och SSTR5 OE-cellerna (figur 18). BON1-cellerna
var transfekterade med 12xCSL-Fluc och SV40-hRluc. Dessutom användes HEK FLN1celler som positiv kontroll. Brunnarna i en 96-håls platta täcktes med 50 µg/ml protein
G och sedan med JAG1-peptid och IgG Fc. JAG1- och IgG Fc-koncentrationerna som
68

användes var 0,1; 0,5; 2 och 5 µg/ml. IgG Fc användes som bakgrundskontroll. Notchaktiviteten ökade då koncentrationen av JAG1-peptider också ökade. Hos BON1 WToch SSTR5 KO-cellerna var CSL-aktiviteten lika medan hos BON1 SSTR5 OE-cellerna
detekterades lägre CSL-aktivitet. CSL-aktiviteten ökade inte efter 2 µg/ml hos BON1
WT- och SSTR5 OE-cellerna.

11.5 Diskussion
Notch signaleringen är viktig för utveckling och differentiering av bukspottskörtelns
neuroendokrina celler. Därför kunde Notch också påverka framåtskridandet av
PNET:er. För att studera om SSTR-uttrycket kunde påverka Notch-receptor- och JAG1proteinuttrycket, användes westernblot. Experimentet visar att SSTR5-uttrycket hos
BON1 WT-, SSTR5 OE-, SSTR5 KO A11- och SSTR5 KO C8-cellerna inte påverkar
JAG1-, Notch1- eller Notch3-uttrycket. Detta tyder på att SSTR5-uttryck inte påverkar
transkriptionen eller translationen av dessa proteiner. Även om skillnader i proteinnivån
inte detekteras, kunde det finnas skillnader i regleringen av Notch-signaleringen genom
posttranslationella modifieringar eller endocytos av Notch-receptorer och ligander. Det
kunde också vara intressant att analysera DLL1-nivåerna hos dessa celler eftersom
DLL1 inhiberar Notch-signaleringen hos proneurala celler (Jensen et al., 2000).
SSTR2 och SSTR5 påverkar cell proliferationen via MAPK-, PI3K- och NOSsignalering,

och

kunde

påverka

proliferations

hastigheten

hos

BON1-celler

(Theodoropoulou & Stalla, 2013). Dessutom kunde skillnader i proliferation kopplas till
Notch-aktivitet eftersom aktivering av Notch i BON1-celler har visats inhibera
cellcykeln (Nakakura et al., 2005). Cellräkning visade att SSTR2- och SSTR5-uttryck
påverkade inte proliferationen hos BON1-cellerna in vitro (figur 13). Däremot, kunde
proliferationsskillnader detekteras mellan BON1-cellerna in vivo och kunde bero på
aktivering av SSTR:er.
WST8-experimentet användes tillsammans med cellräkning eftersom absorbansen från
WST8-reagensen är kopplad till NADH-produktion och mängden metaboliskt aktiva
celler. BON1 SSTR5 KO-celler som odlades i medium med 10 % FBS visade en
signifikant ökning i absorbansnivån vilket kunde kopplas till ökad NADH-produktion
eller proliferation. Eftersom cellräkningen inte antydde en ökad proliferation mellan
BON1-cellerna kunde absorbansökningen antas bero på ökad metabolisk aktivitet. För
att verifiera att dessa celler har ökad metabolisk aktivitet kunde en annan analys för
69

metabolisk aktivitet användas. Då celler odlades i det näringsfattiga mediet med 0,2 %
FBS var absorbansen från WST8-reagensen lägre än då cellerna odlades i medium med
10 % FBS, och skillnader i absorbansnivån detekterades inte mellan BON1-cellerna.
Den låga absorbansen kunde bero på låg proliferations förmåga eller apoptos. Låg
proliferation kunde analyseras med hjälp av proliferations markörer och apoptos kunde
man däremot studera genom analys av caspas-aktivitet.
BON1-cellerna med olika SSTR2- och SSTR5-uttryck visade inte skillnader som
Notch-signalsändande celler. Men då BON1-cellerna användes som signalmottagande
celler i samkultur med 3T3 JAG1-cellerna, observerades ökad CSL-aktivitet hos BON1
SSTR5 KO-cellerna. Eftersom BON1-cellerna inte visade skillnader i Notch-receptoroch JAG1-uttryck kunde detta tyda på att SSTR5 reglerar transkription av Notch
målgener. SSTR5 har en inhiberande effekt på MAPK-, NOS-, cAMP- samt Ca2+signalering, och en aktiverande effekt på PLC-signalering (Theodoropoulou & Stalla,
2013). Dessa signalering räckorna och Ca2+-signalering har tidigare kopplats också till
reglering av Notch-signaleringen (Mckenzie et al., 2005; Hasson & Paroush, 2006;
Bosse et al., 2013; Angulo-Rojo et al., 2013; Nagel et al., 2017).
Aktivering av Notch-signaleringen upprepades hos BON1 WT-, SSTR5 OE- och
SSTR5 KO-cellerna, men denna gång med JAG1-peptider. I detta experiment avvek den
transkriptionella aktiviteten av CSL jämfört med samkultur experimentet genom att
CSL-aktiviteten hos BON1 WT- och SSTR5 KO-cellerna var lika, medan BON1
SSTR5 OE-cellerna visade lägre CSL-aktivitet. Dessutom ökade CSL-aktiviteten inte
efter 2 µg/ml hos BON1 WT- och SSTR5 KO-cellerna. Detta kunde tyda på
signalsaturering

och

kunde

verifieras

genom

att

odla

celler

i

en

högre

peptidkoncentration än 5 µg/ml.
Då Notch aktiverades med JAG1-peptiderna, förväntades liknande resultat som i
samkulturexperimentet. Eftersom resultaten mellan dessa två experimenterna avvek,
kunde det finnas funktionärliga skillnader mellan de två metoderna som påverkade
resultaten. I samkulturexperimentet presenterades JAG1 av 3T3-cellerna och det är
viktigt att veta hur de Notch-signalsändande cellerna är utspridda och hur bra de
kommer i kontakt med BON1-cellerna. Dessutom kunde JAG1-uttrycket hos 3T3
JAG1-cellerna vara låg, eftersom JAG1-uttrycket kan försvinna med tiden. Hos JAG1peptidexperimentet är JAG1-peptiderna fästa till cellkulturs plattan, men hur väl och
vilken väg som peptiderna är fästa till protein G är okänt. Efter som JAG1-peptiderna
70

inte presenteras av celler är det också okänt hur peptiderna inducerar dragningskraftet
som krävs för Notch-aktiveringen. Dessutom kunde peptidkoncentrationen möjligtvis
påverkas då brunnarna i cellodlingsplattan tvättades.
Efter som skillnader i CSL-aktivitet detekteras i samkulturexperimentet och då Notch
aktiveras med JAG1-peptider, kunde man anta att det finns en koppling mellan SSTR5 och
Notch-signalering. I framtiden kunde det vara gynnsamt att studera hur SSTR5 påverkar
den transkriptionella aktiviteten och vilken av de fyra Notch-receptorerna var aktiverad
av JAG1.

71

